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3 Summary 
A significant proportion of the world’s population is affected by hereditary defects in 
one or more of the clotting factors. Haemophilia A is a sex-linked genetic disorder 
resulting in deficiency of plasma factor VIII coagulant activity. Haemophilia B 
(Christmas disease) is due to deficiency of clotting factor IX [7, 8]. The clinical 
manifestations of haemophilia A and haemophilia B are indistinguishable, and occur 
in mild, moderate, and severe forms. The severe form of haemophilia is characterized 
mainly by frequent haemarthroses leading to chronic crippling haemarthropathy 
when not treated very early or prophylactically. Highly purified concentrates, 
prepared from human plasma or manufactured by recombinant technology, are 
available for treatment and are considered safe and effective [1, 2]. 
In developed countries, early treatment of bleeding episodes and home therapy 
quickly evolved as the primary management option. Presence of specialized 
interdisciplinary centres with 24 hours service, training and education of patients are 
the main advantages of the comprehensive treatment concept in developed countries. 
This is not the case in most developing countries where the government does not 
have the resources to buy the necessary quantities of coagulation factors in the face of 
more urgent health priorities and hardly any patients can afford to pay for their own 
treatment even for on-demand home therapy. Other problems are insufficient supply 
with clotting factor concentrates, lack of access to these concentrates and absence of 
specialized care centres [6].  
Haemophilia care in Arabic region shows variations from country to country 
depending on socio economic status and varies from good organized care to absence 
of it at all. Only 13 of 21 Arabic countries have reported at least a Hemophilia Center 
and an organized care provided to haemophiliacs. Factor use per capita is low 
compared to western countries, and none of Arabic countries reached minimal level 
of 1 IU per capita. High income countries, such as Saudi Arabia, have reported a 
larger amount of factor concentrates, compared to those with lower income.  
Haemophilia care in western European countries is a well organized process 
providing a qualified management to all haemophiliacs, through the Haemophilia 
treatment centers (HTCs) which exist in all the EU Member States. Choice and levels 
of treatment, availability of comprehensive care and access to prophylaxis vary 
widely from one Member State to another [31 ,72]. 
Yemen represents those Arabic countries where only a minimal care is provided to 
haemophilic patients. Facing other common and serious health problems, the health 
authorities pay only a small attention to haemophiliacs. In this country with a 
population of over 22 millions, and an estimated number of about 1460 haemophilia 
cases, there is no specialized center for treatment of haemophilia.  
In Germany, people with haemophilia are entitled to a choice of all treatments 
ranging from an optimal level of factor replacement therapy on demand as well as on 
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a prophylactic basis for those who need it, to comprehensive care at a Haemophilia 
Treatment Centre [81]. Haemophilia care in Germany is provided through 12 
specialized Haemophilia Treatment Centers (HTC). Apart from treatment and care at 
the HTCs, specialized physicians in practices and at haematology units in general 
hospitals provide care. Home treatment is available for children as well as for adult 
people suffering from severe haemophilia[72]. 
In this short analysis, 20 Yemeni haemophilic patients were compared to 40 German 
patients. We analyzed demographic data, clinical manifestations, treatment options, 
complications and costs. The majority of Yemeni haemophiliacs, about 60 % of them, 
were children and the peak age was only 29 years. Alarming evidence is the fact that 
the Yemeni haematologists have not reported any patient older than 30 years. 
In Yemen, despite the sufficient number of specialized haematologists, only two 
general hospitals located in the capital city provide some care to haemophilic 
patients. This care includes no prophylaxis program but only treatment on demand. 
It is offered only to severe affected cases and is based still on old medications such as 
Cryoprecipitate, FFP and DDAVP. About 65 % of the total cases participating in our 
study were treated with factor concentrates, which, even in cases with life 
threatening manifestations was not given in adequate amounts. During a period of 6 
months, severe affected Yemeni haemophiliacs received an average of 1.157 IU of 
factor concentrates, or 90 times less than a German one. Access to factor concentrates 
was very difficult even for severe affected Yemeni haemophiliacs.  
The awareness and education about the nature of disease among Yemeni 
haemophiliacs and their relatives is low, especially in rural areas, where most of 
Yemeni population lives. Couples who have haemophilic boys want to have still 
other children; circumcision, done routinely for all boys, is performed at home by a 
nurse, usually within the first 4 weeks of life, resulting in life threatening bleeding for 
haemophiliacs.  
Absence of the health insurance system is another big challenge, as the patient 
should pay for every kind of health care and the costs of treatment are high 
compared to the income. The cost of care among Yemeni haemophilic patients 
during last 6 months varied from EUR 200 to EUR 2000, with an average of EUR 865 
per patient. This amount of money exceeds the average of annual income among 
Yemeni population.  
Under such conditions, without a health insurance, haemophilic patients face a big 
challenge on dealing with complications of the disease like transmitted infections or 
musculoskeletal complications. Facing those problems, the chances to survive are 
low and no haemophilic patient reaches the fourth decade of life. In a country as 
Yemen, where neither government nor the patient are able to pay for an adequate 
management of haemophilia,until now there is no initiative for creation of donators 
found in order to support people affected by this disease. 
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As a conclusion, we consider that the major problems facing haemophilia care in 
Yemen include: absence of a specialized center for treatment of haemophilia, 
inadequate supply with factor concentrates and lack of awareness and education 
about the nature of the disease.   
We consider that the following recommendations will be useful for improvement of 
haemophilia care in Yemen: 
• Initiation of a first step for a Haemophilia Center in Sana’a, as a result of
coordination between Yemeni authorities and WFH representative for Arabic
Region
• Stimulation of a humanitarian financial support for Yemeni haemophiliacs,
from rich Arabic neighbor countries (Saudi Arabia, Emirates, Qatar, Kuwait)
• Formulation of educational guidelines for haemophiliacs about the nature of
the disease
• Organization of a national network and creation of a registry for
haemophiliacs
• Home therapy (living far away from capital city, Yemeni haemophiliacs have
to cross hundreds of miles to seek for some care)
• A twinning program between haemophilia centers in Germany and clinics
dealing with haemophilia in Yemen.
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Zusammenfassung 
Erbliche Defekte in einem oder mehreren der Gerinnungsfaktoren gehören zu den 
seltenen Erkrankungen, sogenannten „Orphan diseases“. Hämophilie A ist eine 
geschlechtsgekoppelte genetische Erkrankung gekennzeichnet durch einen Mangel 
an Faktor VIII Gerinnungsaktivität. Bei Hämophilie B (Christmas disease) liegt der 
Defekt im Gerinnungsfaktor IX. Die klinische Symptome der Hämophilie A und 
Hämophilie B sind nicht unterscheidbar, und umfassen leichte, mittelschwere und 
schwere Formen. Die schwere Form der Hämophilie zeichnet sich durch häufige 
Gelenkblutungen aus, die zu schweren Gelenkdeformitäten und Verkrüppelung 
führen, wenn sie nicht rechtzeitig behandelt werden. Hochgereinigte Konzentrate, 
die aus humanem Plasma oder durch rekombinante Technologie hergestellt werden, 
sind für die Behandlung verfügbar und gelten als sicher und effektiv[1, 2]. 
In den entwickelten Ländern, ist eine Primärphrophylaxe mit Faktor VIII bei Kindern 
die Therapie der Wahl mit einer kontinuierlichen Faktor VIII Gabe durch „Home 
Therapy“, also Schulung der Eltern und Behandlung zu Hause. Organisation der 
Therapie in spezialisierten interdisziplinären Zentren mit 24-Stunden-Service, 
Schulung und Ausbildung von Patienten aller Altersgruppen, und sofortige 
Behandlung von Blutungen sind die wichtigsten Vorteile dieses umfassenden 
Behandlungskonzepts. Dies ist nicht der Fall in den meisten Entwicklungsländern, in 
denen die Regierung keine Finanzmittel bereitstellen kann, um die erforderlichen 
Mengen an Gerinnungsfaktoren zu kaufen. Die Patienten können es sich nicht leisten, 
die teure Faktor VIII-Behandlung zu bezahlen, auch nicht eine on-demand Therapie 
akuter Blutungen zu Hause. Grundsätzliche Probleme sind unzureichende 
Versorgung mit Gerinnungsfaktor-Konzentraten, fehlender Zugang zu ärztlicher 
Versorgung und das Fehlen spezialisierter Pflegeeinrichtungen[6]. 
Hämophilie Behandlung im arabischen Gebiet zeigt Variationen von Land zu Land je 
nach sozio-ökonomischem Status und variiert von gut organisierter Pflege bis 
völliger Abwesenheit einer Behandlungsmöglichkeit. Nur 13 von 21 arabischen 
Ländern haben überhaupt mindestens ein Hämophiliezentrum und eine organisierte 
Versorgung von Hämophilie-Patienten gemeldet. Faktor VIII Verbrauch pro Kopf ist 
im Vergleich zu westlichen Ländern gering, und kein einziges der arabischen Länder 
erreicht ein minimales Niveau von 1 IU Faktor VIII Verbrauch pro Kopf. Länder mit 
hohem Einkommen, wie Saudi-Arabien, haben einen größeren Verbrauch von Faktor 
VIII Konzentrat, im Vergleich zu arabischen Ländern mit niedrigerem Pro-Kopf-
Einkommen ausgewiesen[31 ,72]. 
Jemen represäntiert die arabische Länder, in denen nur eine minimale Versorgung 
für hämophile Patienten erreichbar ist. Im Vergleich zu anderen überwiegenden , 
ernsthaften Erkrankungen, beachten die Gesundheitsbehörden hämophilie Patienten 
nur wenig. In diesem Land mit einer Bevölkerung von über 22 Millionen und einer 
geschätzten Anzahl von ca. 1460 Hämophilie Fällen, gibt es kein einziges 
spezialisiertes Zentrum für die Behandlung von Hämophilie-Patienten. 
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Hämophilie Behandlung in den westeuropäischen Ländern ist dagegen 
hervorragend organisiert und bietet qualifizierte Versorgung für alle Hämophilie-
Patienten durch spezielle Hämophilie-Behandlungszentren an, die in allen EU-
Mitgliedstaaten bestehen. Auswahl und Ebenen der Behandlung, die Verfügbarkeit 
einer umfassenden Versorgung, Faktor VIII Verbrauch und Zugang zu Prophylaxe 
variieren jedoch auch hier stark von einem Mitgliedstaat zum anderen .  
In Deutschland können Patienten mit Hämophilie das Faktor VIII Konzentrat frei 
wählen, und erhalten eine umfassende Betreuung und Anleitung in 12 Hämophilie 
Behandlungs Zentren. Zusätzlich unterstützen spezialisierte Ärzte in Praxen und 
Krankenhäusern die Behandlung der Hämophilie Patienten. Prophylaxe ist für alle 
Kinder mit schwerer Hämophilie vorgesehen, sowie für erwachsene Patienten mit 
schwerer Hämophilie bei Bedarf[72]. 
In der vorliegenden Arbeit wurden 20 jemenitische Hämophilie Patienten mit 40 
deutschen Hämophilie Patienten verglichen. Demographische Daten, klinische 
Erscheinungsformen, Behandlungsmöglichkeiten, Komplikationen und Kosten 
wurden in beiden Patientengruppen analysiert. Etwa 60% der jemenitischen 
Hämophilie Patienten waren Kinder. Der älteste Hämophilie Patient in dieser 
Gruppe was 29 Jahre alt. Laut Bericht jemenitischer Hämatologen wurde in der 
Abteilung kein Hämophilie Patient mit einem Alter über 30 Jahren gesehen. 
Im Jemen bieten trotz einer ausreichenden Anzahl von spezialisierten Hämatologen 
nur zwei allgemeine Krankenhäuser in der Hauptstadt eine Minimalversorgung für 
Hämophilie Patienten an. Diese Versorgung umfasst kein Prophylaxe-Programm für 
Kinder mit Faktor VIII, sondern nur die Behandlung akuter Blutungen in schweren 
Fällen überwiegend mit veralteten Präparaten wie Kryopräzipitat, FFP und DDAVP. 
In über 65% der Gesamtzahl der Fälle, die in unserer Studie teilgenommen haben, 
wurden Faktor-Konzentrate gegeben, allerdings auch in Fällen mit 
lebensbedrohlichen Manifestationen nicht in ausreichender Menge. Während eines 
Beobachtungszeitraums von sechs Monaten erhielten die jemenitischen Patienten mit 
schwerer Hämophilie durchschnittlich 1.157 IE Faktor-Konzentrat (pro Patient), das 
heißt 90-mal weniger als ein deutscher Patient mit schwerer Hämophilie. Der 
Zugang zu Faktor VIII Konzentrat war auch für jemenitische Patienten mit schwerer 
Hämophilie und lebensbedrohlichen Blutungen sehr schwierig. 
Die Sensibilisierung und Aufklärung über das Wesen der Krankheit unter 
jemenitischen Hämophilie Patienten und ihren Angehörigen ist niedrig, vor allem in 
ländlichen Gebieten, in denen der größte Teil der jemenitischen Bevölkerung lebt. 
Ehepaare mit hämophilen Jungen wollen noch andere Kinder haben. Die 
Beschneidung, die routinemäßig bei allen Jungen erfolgt, wird meistens zu Hause 
von einer Krankenschwester durchgeführt. Dies geschieht in der Regel innerhalb der 
ersten vier Lebenswochen und kann zu einer lebensbedrohlichen Blutung führen. 
Das Fehlen jeglicher Krankenversicherung ist eine weitere große Herausforderung, 
da der Patient für jede Art von Gesundheitsversorgung die Kosten der Behandlung 
selbst übernehmen muss. Die Kosten für die Behandlung bei jemenitischen 
Hämophilie Patienten im Beobachtungszeitraum von sechs Monaten variierte von 
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EUR 200 bis EUR 2000, mit durchschnittlichen Kosten von EUR 865 pro Patient. 
Dieser Betrag übersteigt das durchschnittliche Jahreseinkommen der jemenitischen 
Bevölkerung. 
Die Überlebenschancen jemenitischer Hämophilie Patienten sind gering und kein 
Hämophilier erreicht das vierte Lebensjahrzehnt. In einem Land wie Jemen, wo 
weder Regierung noch der Patient in der Lage sind für eine angemessene 
Behandlung der Hämophilie zu zahlen, gibt es bis jetzt keine Initiative zur 
Bereitstellung von Spendengeldern um Menschen, die von dieser Krankheit betroffen 
sind, zu helfen. 
Die großen Probleme der Hämophilie Versorgung im Jemen lassen sich wie folgt 
zusammenfassen: unzureichende Versorgung mit und Zugang zu Faktor 
Konzentraten, Abwesenheit von spezialisierten Zentren für die Behandlung von 
Hämophilie Patienten und unzureichende Aufklärung über die Art der Krankheit in 
der Bevölkerung, insbesondere in Zusammenhang mit der frühzeitigen 
Beschneidung der männllichen Kinder.  
Folgende Empfehlungen zur Verbesserung der Hämophilie Behandlung in Jemen 
lassen sich daraus ableiten: 
• Gündung eines Hämophilie-Zentrums in der Hauptstadt Sana'a, durch eine
Kooperation der jemenitischen Behörden mit WHF Vertretern für die arabische 
Region 
• Beginn einer humanitären finanziellen Unterstützung für jemenitische Hämophilie
Patienten, mit Hilfe reicher arabischer Nachbarländer (Saudi-Arabien, Emirate, Qatar, 
Kuwait) 
• Aufklärung von Hämophilie Patienten und ihrer Familien über die Art der
Krankheit und ihre Folgen 
• Organisation eines nationalen Netzes und die Schaffung eines Registers für
Hämophilie Patienten 
• Home-Therapie (weit weg von der Hauptstadt, müssen jemenitische Hämophilie
Patienten Hunderte von Meilen durchqueren, um eine Behaldlung zu bekommen) 
• Gründung eines Twinning-Programms zwischen Hämophilie-Zentren in
Deutschland und hämatologischen Kliniken in Jemen. 
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4 Introduction 
A significant proportion of the world’s population is affected by hereditary defects in 
one or more of the clotting factors. These defects lead to abnormal and sometimes 
life-threatening bleeding episodes.  
Haemophilia is a group of X-linked bleeding disorders due to deficiency of clotting 
factors VIII (Haemophilia A) and IX (Haemophilia B). The clinical manifestations of 
haemophilia A and haemophilia B are indistinguishable, and occur in mild, moderate, 
and severe forms. They are the only blood clotting disorders inherited in a sex-linked 
pattern. The severe forms of haemophilia are characterized mainly by frequent 
haemarthroses leading to chronic crippling haemarthropathy when not treated very 
early or prophylactically. Highly purified concentrates, prepared from human 
plasma and manufactured by recombinant technology, are available for treatment 
and are considered to be safe and effective. The main complication of treatment is the 
development of antibody inhibitors against either factor VIII or factor IX, which are 
more common in patients with haemophilia A than in patients with haemophilia B[1, 
2].
Haemophilia is the most severe bleeding disorder, after von Willebrand's disease 
which is the most common congenital bleeding disorder overall. In 2009, the World 
Federation of Haemophilia (WFH) has identified 153,251 people with haemophilia 
throughout the world[3]. This estimation included 91 % of world population. 
The WFH estimates that the majority of people with haemophilia in the world do not 
receive adequate care. Seventy-five per cent of the global haemophiliacs lives in 
developing countries, where probably only one in five cases is diagnosed, and there 
is little or no care available[4]. 
Prior to the 1960s, when no adequate treatment was available, individuals with 
haemophilia suffered a similar fate worldwide. Severe joint disabilities appeared in 
early teens, and most patients died before the age of 20. At this time Haemophilia 
was treated primarily with fresh blood transfusions. Discovery of cryoprecipitate and 
subsequent development of clotting factor concentrates dramatically increased 
clinical management options. As concentrates could be easily stored, administered at 
home and carried with patients during travel, patients began to adopt a practice of 
home therapy[5]. 
Haemophilia as a disease and its management has a large impact on the community, 
including social integration and economics. Inability to be an active part of society 
and high cost of the medical care make this disease an important problem for all 
haemophilic patients.  
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In developed countries, early treatment of bleeding episodes and home therapy 
quickly evolved as the primary management option. Presence of specialized 
interdisciplinary centres, training and education of patients are the main advantages 
of the comprehensive treatment concept in developed countries.  
This is not the case in most developing countries where the government does not 
have the resources to buy the necessary quantities of coagulation factors in the face of 
more urgent health priorities and hardly any patients can afford to pay for their own 
treatment even for on-demand home therapy. Other problems are insufficient supply 
with clotting factor concentrates, lack of access to these concentrates and absence of 
specialized care centres [6].  
In this short analysis we have taken two examples from two different parts of the 
world, Yemen and Germany. There is a big gap between these two countries 
regarding education, socio-economic status, health care and also haemophilia care, 
and we can assume that these two countries represent two extremities regarding 
health services provided to the community.  
Taking in consideration that Germany has an advanced health care system with 
many facilities, potential human and financial resources, we want to find out the 
recent ways and strategies used for management of Haemophilia. On the other hand 
we have chosen Yemen, for two reasons: first, it is one of the developing countries 
facing many challenges in different fields of life, among which is the health care; and 
second, I studied there having the chance to know and touch the reality of this 
country. This Arabic country, rich in natural resources such as oil and gas, is 
suffering since many years from political crisis and instability, leading civil wars, 
poverty, absence of proper health care and education.  
The primary objective of this study is to define useful recommendations and advices 
for clinics and hospitals that concern with this disease in Yemen. For that reason we 
will describe the management of haemophilia in Yemen and identify the major 
challenges and problems regarding the haemophilia care in this country. After that, 
will be described the management of haemophilia in western European countries, 
particularly in Germany.  
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5 Theoretical part 
5.1 Haemophilia 
5.1.1 Definition 
Haemophilia A is a sex-linked genetic disorder resulting in deficiency of plasma 
factor VIII coagulant activity. Haemophilia B (Christmas disease) is due to deficiency 
of clotting factor IX[7, 8]. 
5.1.2 Epidemiology 
The incidence of haemophilia A is 1 in 10,000 live births, or 1 in 5,000 male births. 
Haemophilia B is less common with an incidence of 1 in 30,000 live male births. The 
prevalence rates are  105 and 28 per million male population for Haemophilia A and 
Haemophilia B respectively[4]. In 2009, 153,251 people with haemophilia throughout 
the world have been documented in a survey which included 105 countries and 
about 91 % of world’s population. About 43% of total documented haemophiliacs 
severe affected cases [3, 9]. 
5.1.3  Genetics 
The factor VIII and factor IX genes are located on the X chromosome. Many different 
defects in the gene have been identified, ranging from single-base changes to 
deletions and inversions. Major disruption of the gene, e.g. a large deletion, results in 
severe haemophilia whereas a single base change will only cause a partial loss of 
function, with moderate or mild disease [10]. As the factors’ gene is on the X 
chromosome, haemophilia is a sex-linked disorder. Thus all daughters of 
haemophiliacs are obligate carriers and sisters have a 50% chance of being a carrier. If 
a carrier has a son, he has a 50% chance of having haemophilia, and a daughter has a 
50% chance of being a carrier. Carriers generally have adequate levels (> 60%) of 
clotting FVIII or FIX to control bleeding. However, clotting factor levels vary from 
one carrier to another due to lyonization, in which the expression of one of the two X 
chromosomes is randomly suppressed [11, 12]. A reduced factor VIII or IX level in a 
carrier will result in a mild bleeding disorder; thus all known or suspected carriers of 
haemophilia should have their factor VIII or factor IX level measured[10, 12]. 
5.1.4 Diagnosis 
5.1.4.1 Clinical features 
Haemophilia results in prolonged oozing after injuries, tooth extractions, or surgery, 
and delayed or recurrent bleeding prior to complete wound healing. The age of 
diagnosis and frequency of bleeding episodes are related to the factor VIII clotting 
activity[7, 8]. 
It occurs in mild, moderate, and severe forms. Although patients with mild 
haemophilia usually bleed only after trauma or surgery, those with severe 
haemophilia A or B bleed spontaneously or after trivial trauma, particularly into 
joints and muscles[13].Soft tissue haematomas and haemarthroses leading to severe, 
crippling haemarthropathy are  characteristic of the disease[14]. Subacute 
haemarthroses is generally associated with previous synovitis or arthropathy, while 
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acute haemarthroses commonly occurs in a previously healthy joint. Acute bleeding 
is usually felt by the patient as a burning sensation in the joint. Haemarthroses 
develops within a few hours; the joint becomes inflamed, tense, warm, and the skin 
becomes bright red. The affected joint is held in an antalgic flexion position, with 
painful and limited mobility[15, 16]. 
Muscle haematomas are also characteristic of haemophilia. These occur most 
commonly in the calf and psoas muscles but they can arise in almost any muscle. The 
untreated child almost always has subcutaneous hematomas; some have been 
referred for evaluation of possible non-accidental trauma[7, 8]. 
Haematuria is less common than joint or muscle bleeding in individuals with 
haemophilia, but the most severely affected patients, have one or two episodes per 
decade. These may be painless and resolve spontaneously, but, if bleeding is heavy, 
it can produce clot colic. Clots may obstruct renal tubules or the ureter, causing 
temporary hydronephrosis[16]. 
Possibly the most frequently encountered emergent haemorrhagic event in 
haemophilia management is central nervous system (CNS) bleeding. Most of these 
events, which involve bleeding inside the skull or spinal canal, are caused by trauma. 
However, since patients with haemophilia can experience bleeding even weeks after 
a minor head injury, a history of head trauma may be hard to determine, particularly 
in children[17, 18]. 
Intestinal tract bleeding usually presents as obstruction due to intramural 
haemorrhage, but haematemesis and melaena also occasionally occur and should be 
routinely investigated, as they may be due to peptic ulcer or malignancy[16]. 
There is a wide spectrum of esophageal and gastrointestinal (GI) bleeding. A review 
of 41 episodes of gastrointestinal bleeding in one institution over 10 years implicated 
duodenal ulcer (22%) and gastritis (14%) as the most common source. In 22%, no 
source was identified. Mallory-Weiss Syndrome has also been cited as a cause for 
upper GI bleeding in haemophilia patients[20].
Surgery and open trauma invariably lead to dangerous haemorrhage in the untreated 
individual with haemophilia. There may be persistence of haemorrhage often after 
an initial short lived period of haemostasis. The incidence of bleeding in different 
sites is given in the tables 1 and 2[14].  
Table 1: Incidence of different sites of bleeding in percentages 
Site of bleeding Incidence in percentage 
Haemarthroses 70%-80% 
Muscle/soft tissue 10%-20% 
Other major bleeds 5%-10% 
Central nervous system (CNS) bleeds < 5% 
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Table 2: Incidence of bleeding in different joints 
Joint Incidence of bleeding in % 
Knee 45% 
Elbow 30% 
Ankle 15% 
Shoulder 3% 
Wrist 3% 
Hip 2% 
Other 2% 
5.1.4.2 Laboratory findings 
Evaluation of an individual with a suspected bleeding disorder includes: platelet 
count and platelet function analysis (PFA closure times) or bleeding time, activated 
partial thromboplastin time (APTT), and prothrombin time (PT). Thrombin time 
and/or plasma concentration of fibrinogen can be useful for rare disorders[7, 8]. 
Screening tests show a long activated partial thromboplastin time (APTT), normal 
prothrombin time (PT), thrombin clotting time (TCT) and bleeding time, and a 
normal platelet count. Specific assays show factors VIII and IX clotting activity below 
0.05 U/mL, with all other factors normal[21]. 
The normal level of factors VIII and IX is 50-150% and is measured by a clotting 
assay[7, 8]. In haemophilia the propensity to bleeding is related to the plasma factor 
VIII level. The classification of severity of haemophilia is set out in the Table 3[22]: 
Table 3: Classification of severity of haemophilia 
Severity Clotting factor level % activity (IU/ml) Bleeding episodes 
Severe 1% (< 0.01) Spontaneous bleeding, predominantly in joints and muscles 
Moderate 1%-5% (0.01-0.05) Occasional spontaneous bleeding. Severe bleeding with trauma, surgery 
Mild 5%-40% (0.05-0.40) Severe bleeding with major trauma 
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5.1.5 Treatment 
The major precept of haemophilia care consists of adequate replacement of the 
deficient coagulation factor protein so as to prevent or reverse acute bleeding 
episodes. This is most effectively and efficiently accomplished by the administration 
of clotting factor concentrates, which contain an abundance of the specific deficient 
coagulation factor [23]. 
5.1.5.1 Clotting factor concentrates 
Modern management of haemophilia began in the 1960’s when the first FVIII plasma 
concentrates became available. This first generation of FVIII enabled a much more 
effective treatment than simple plasma. The life expectancy and quality of life   saw 
unprecedented improvement[24].The effect of replacement therapy has significantly 
improved the morbidity and mortality of people with haemophilia[25]. 
The introduction of coagulation factor replacement therapy over the past half century 
has greatly contributed to the improvement in care of people with haemophilia [26].
Following the sequencing of the FVIII gene in 1984, the various mutations were 
identified (meaning that the severity of haemophilia and probability of the 
occurrence of inhibitors could be predicted) and the first recombinant concentrates 
were developed. The first generation of these rFVIII was licensed in 1993. Production 
of rFVIII using genetic engineering in theory eliminates the risk of infection by a 
human virus[13, 24]. Hamster cells are transfected with human clotting factor genes 
by recombinant DNA technology. Factor VIII produced by recombinant DNA 
techniques is available, safe, and effective[16].
5.1.5.2 DDAVP 
Desmopressin (1-deamino-8-D-arginine vasopressin, also known as DDAVP) is a 
synthetic analogue of antidiuretic hormone (ADH). The compound boosts the plasma 
levels of FVIII and vWF after administration [22]. It can be used to treat mild 
haemophilia. This synthetic analogue of vasopressin retains the antidiuretic action of 
the natural hormone and also stimulates the release of tissue plasminogen activator. 
In practice, these effects can be used to elevate the plasma factor VIII level two- to 
fourfold above the baseline, presumably by its release from storage site(s). DDAVP is 
contraindicated in elderly patients and those with vascular disease, because arterial 
thrombosis is a theoretical risk and has been reported following DDAVP in these 
circumstances[27]. 
5.1.5.3 Gene therapy 
Haemophilia continues to represent a leading candidate condition for the successful 
application of gene therapy[28].The ultimate goal of gene therapy is the replacement 
of a defective gene sequence with a corrected version to eliminate disease for the 
lifetime of the patient[29]. Although new paths to treatment are available, the path to 
a cure still has barriers that must be overcome. Whether some of these approaches 
might be applicable to human patients with inhibitory antibodies is not yet known, 
and additional preclinical studies are still needed [30]. 
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5.1.5.4 Comprehensive Care Concept 
Comprehensive haemophilia care has been defined as the continuing supervision of 
all medical and psychosocial factors affecting the person with haemophilia [31]. 
Comprehensive care is vital for patients with haemophilia to prevent early death and 
free patients from the complications that inhibit living normal lives. Experience has 
shown that once introduced in a country, there is a progressive restoration of normal 
healthy lives to the haemophilia community[5]. 
Services offered by haemophilia treatment centres (HTCs) adopting the 
comprehensive care model include establishing prophylaxis and other treatment 
protocols, development of psychosocial, education and research programme, 
maintenance of a patient registry, genetic and reference diagnostic services, 
orchestration and management of a wide variety of multidisciplinary interventions. 
Most centres practising this model of care are based in developed countries and can 
meet costs for plentiful treatment products through government or insurance-
company funding. Not all the programmes are dependent on the level of product 
supply, however, many have been supported in countries with emerging economies 
as part of national healthcare systems, particularly in relation to blood 
management[31]. 
As the management of haemophilia is complex, it is essential that those with the 
disorder should have ready 24 hours access to a range of services provided by a 
multidisciplinary team of specialists [32]. Haemophilia is a relatively rare but 
complex disorder in terms of diagnosis and management. Optimal management of 
these patients, especially those with severe forms of the disease, requires more than 
the treatment and prevention of acute bleeding. Keys to improvement of health and 
quality of life include[33]: 
•Prevention of bleeding
•Long-term management of joint and muscle damage and other sequelae of bleeding
•Management of complications from treatment including inhibitor development and
viral infection(s) transmitted through blood products requiring long-term 
management. 
These management goals are best met by a team of healthcare professionals 
providing comprehensive care. Haemophilia patients should ideally be managed in a 
comprehensive care centre staffed by the following core team members [31]: 
• Haematologist(s);
• Nurse coordinator;
• Physiotherapist; and
• Social worker.
These staff members should have expertise and experience in treating bleeding 
disorders. The core team members should have access to the following support 
resources[22]: 
• A coagulation laboratory capable of clotting factor assays and inhibitor detection;
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• Appropriate clotting factor concentrates, either plasma derived or recombinant;
• If clotting factor concentrates are not available, a blood bank with expertise in
preparing fresh frozen plasma (FFP) and cryoprecipitate. 
Specialists should be available as consultants, as needed, and should include, among 
others, the followings[33]. 
• Orthopedic surgeon;
• Physiatrist/rheumatologist;
• Occupational therapist;
• Dentist;
• Geneticist;
• Hepatologist;
• Infectious disease specialist; and
• Immunologist.
In centres where there are many patients with chronic musculoskeletal problems 
from frequent bleeding, an orthopaedic surgeon should be a core team member.  
5.1.6 Prophylaxis 
Prophylaxis is defined as treatment by intravenous injection of factor concentrates in 
anticipation of and in order to prevent bleeding[34].It is recommended as preventive 
therapy for young boys with severe haemophilia in countries where safe factor 
concentrates are available[35].Prophylaxis can prevent joint damage and decrease the 
frequency of joint and other hemorrhages in young boys with severe hemophilia 
A[36].To prevent hemophilic arthropathy, prophylactic treatment of children with 
severe haemophilia should be started before joint damage has occurred[37]. 
Many studies demonstrate the advantage of continuous FVIII prophylaxis over on-
demand treatment in haemophilia A patients. Continuous prophylaxis reduces the 
number of bleeding episodes significantly. However, it cannot prevent bleeds 
completely and requires an almost 4-fold higher consumption of FVIII[38].
Prophylactic factor replacement therapy prevents the occurrence of joint bleeds and 
reduces the overall risk of disability associated with joint bleeds in haemophilia 
patients [39]. While primary prophylaxis(i.e. regular continuous long-term infusion 
of factor concentrates started before the age of two years and/or after no more than 
one joint bleed) is nowadays considered the gold standard for preserving joint 
function in patients with severe haemophilia, the benefits of secondary prophylaxis 
(i.e. all the long term regular treatments not fulfilling the criteria of primary 
prophylaxis) are still controversial[40]. 
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5.1.7 Complications of Haemophilia 
5.1.7.1 Complications of therapy 
5.1.7.1.1 Immunological reactions 
The immune response to factor VIII and factor IX, and the development of inhibitory 
antibodies is a complex multi-factorial process involving a variety of immune 
regulatory genes and cells, several of which have the potential to determine risk[41]. 
The development of inhibitors has been characterized as the most serious remaining 
complication of clotting factor treatment in persons with severe hemophilia. The 
characteristics of the mutation responsible for the disease is the strongest predictor of 
the risk of inhibitor development so far identified, but other genetic and 
environmental factors clearly are also involved[42]. 
Recent evidence suggests that alongside the strong genetic contribution to inhibitor 
formation, there are a number of non-genetic factors which promote formation of 
inhibitors [43]. Based on studies from around the world, it is estimated that the 
incidence of antibody development in persons with severe or moderately severe 
hemophilia A is between 20% and 33%. Among persons with haemophilia B, 
inhibitors are much less frequent, affecting only 1-6%[44]. 
Factors that appear to affect inhibitor development include the severity of 
haemophilia, age, genetics, and, possibly, the type of replacement therapy 
administered. Recent studies raise the concern that recombinant factor therapies may 
be associated with more rapid development and higher levels of inhibitors in 
previously untreated patients [33]. 
Management of patients with inhibitors involves control of acute bleeding episodes 
and, over the long term, induction of immune tolerance for the coagulation 
replacement therapy. Many with low or moderate levels of inhibitors may be treated 
simply by administering higher doses of dotting factor. Other therapies appropriate 
for those with high levels of inhibitors include porcine factor VIII and factor VIII 
bypassing agents, such as recombinant factor VIIa. Long-term immune tolerance has 
been achieved through the high-dose Bonn regimen and immunosuppressive 
regimens such as the Malmö method. Although management of inhibitor patients 
has improved, it still represents a major challenge [45]. 
Once replacement therapy is ineffective, acute management of bleeding requires 
agents that bypass factor VIII activity. Long-term management consists of eradicating 
the inhibitor through immune tolerance. Despite success in the treatment of acute 
bleeding and inhibitor eradication, there remains an inability to predict or prevent 
inhibitor formation. Ideally, prediction and ultimately prevention will come with an 
improved understanding of how patient specific and treatment-related factors work 
together to influence anti–factor VIII antibody production[46]. 
18 
5.1.7.2 Infectious Complications 
5.1.7.2.1 Hepatitis 
Almost all multitransfused haemophilia patients treated before 1985 were infected 
with one or more agents of viral hepatitis. Although many infected patients did not 
suffer acute symptoms, at least 50 percent developed chronic persistent or chronic 
active hepatitis that led to cirrhosis[47]. The antigen-positive adult patients 
frequently have a superimposed infection with the delta agent, leading to severe 
active hepatitis and cirrhosis and an increased risk of hepatocellular carcinoma. 
Therapy with recombinant interferon alpha and ribavirin can reduce viral load and 
improve survival of affected patients[48]. A considerable number of these patients 
were also infected with human immunodeficiency virus (HIV)[49]. 
5.1.7.2.2 Human Immunodeficiency Virus (HIV) 
Many individuals who received blood products from 1979 to 1985 contracted HIV. 
Approximately half of these individuals died of AIDS prior to the advent of effective 
HIV therapy[8]. Most HIV infection in the haemophilic population occurred before 
the virus was discovered and therefore before individual donor testing was 
introduced [50, 51]. 
Following the identification in 1984 of HIV as the causative agent of AIDS, 
investigators discovered that heat treatment (60°C for more than two hours) of 
concentrated clotting factors inactivated HIV. This, with the development of 
serologic methods to screen blood for HIV and the self-deferral of high-risk blood 
donors, minimized further risk of infection in persons with haemophilia[52]. 
5.1.7.2.3 Prions 
Prions are infectious particles consisting of proteinaceous material devoid of a 
nucleic acid genome. Creutzfeldt-Jakob disease (CJD) is a member of a group of 
diseases known as Transmissible Spongiform Encephalopathies (TSEs) or prion 
diseases[53]. These are rare, fatal disorders that result in the progressive destruction 
of the nervous system. The potential for transmission of CJD through contaminated 
blood and blood products is of particular concern for the bleeding disorders 
community. Some studies support the idea that transmission of CJD by blood 
transfusions or blood products is very rare if it exists. However, because of the short 
incubation times seen in the studies and the very small number of cases, no one can 
definitely say that transmission is nonexistent[54]. 
5.1.7.3 Musculoskeletal complications 
5.1.7.3.1 Muscle Haematomas 
Haemorrhages in muscle or soft tissue are particularly dangerous when they occur in 
closed compartments, such as the volar aspect of the wrist and forearm, the deep 
palmar compartments of the hand, or the anterior or posterior tibial compartments. 
Such nerve compression due to a closed space hemorrhage, known as “compartment 
syndrome,” can compromise limb function [55].  
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5.1.7.3.2 Chronic haemophilic arthropathy 
The most common complication of haemophilia is crippling joint disease. The 
degeneration of a normal joint after recurrent bleeds is a result of a number of 
mechanisms which finally interact to produce severe distortion[56]. This can develop 
any time from the second decade of life, sometimes earlier, depending on the severity 
of bleeding and its treatment. With advancing cartilage loss, a progressive arthritis 
condition develops along with secondary soft tissue contractures, muscle atrophy, 
and angular deformities.  The goal of treatment is to improve joint function and 
relieve pain. Supervised physiotherapy is a very important part of management at 
this stage. Factor replacement is necessary if recurrent bleeding occurs during 
physiotherapy. Pain should be controlled with appropriate analgesics. If these 
conservative measures fail to provide satisfactory relief of pain and improved 
function, surgical intervention may be considered[14]. 
Between the second and fourth decades, many haemophiliac patients develop severe 
articular destruction. At this stage possible treatments include joint debridement, 
arthrodesis and arthroplasty[57]. 
Total joint replacement has been successfully performed in people with haemophilia 
for over 30 years. By far the greatest numbers have been total knee replacements. The 
benefits of pain relief and improved function provided by total joint replacement 
make this procedure the most successful orthopedic operation for managing chronic 
hemophilic arthropathy[58]. 
5.1.7.3.3 Chronic synovitis 
The origin of haemophilic synovitis is clearly related to chronic accumulation of 
blood within a joint [59]. With repeated bleeding in a joint, the synovium becomes 
chronically inflamed and eventually hypertrophies, causing the joint to appear 
grossly swollen. This swelling is usually not tense, nor is it particularly painful. 
Diagnosis made by performing a detailed physical examination of the joint. The 
presence of synovial hypertrophy may be confirmed by ultrasonography and MRI. 
Plain radiographs and particularly MRI will assist in defining the extent of articular 
changes. The goal of treatment is to control the synovitis and maintain good joint 
function[14]. 
It has long been recognized that the emergence of chronic haemophilic 
haemarthroses is incited by a hypertrophic and highly vascular synovium and that 
removal of this synovium is the key to prevention of further joint damage. Removal 
of the synovium can be accomplished through surgical and non-surgical 
procedures[60]. 
5.1.7.3.4 Pseudotumour formation  
Pseudotumors are blood cysts that occur in soft tissues or bone. They are rare but 
dangerous complications of haemophilia. Most pseudotumors are not associated 
with pain unless rapid growth or nerve compression occurs. They usually contain 
either serosanguineous fluid or a viscous brownish material surrounded by a fibrous 
membrane. Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) 
is useful for diagnosis. Needle biopsies of pseudotumors should be avoided because 
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of the risk of infection and haemorrhage. Surgical management is the most effective 
treatment for pseudotumor, although more conservative therapies cannot be 
overlooked in selected cases [61, 62]. 
While pseudotumors in patients with haemophilia are in themselves not haemophilic 
emergencies, an acute rupture of a large pseudotumour in the pelvis or thigh may 
lead to acute hypotension from blood loss. When such an event occurs, an immediate 
correction of the FVIII or FIX level is indicated, while keeping in mind that the 
presence of chronic clots with fibrinolysis in the pseudotumour may also predispose 
to further haemorrhage[55]. 
5.1.7.3.5 Fracture 
Fractures are not uncommon in the person with haemophilia and occur most 
commonly around the knee and hip. The person with haemophilia is at risk for 
fracturing around joints that have significant loss of motion and in bones that are 
osteoporotic. Fractures managed with closed reduction and casts require clotting 
factor replacement therapy for 3-4 days, until swelling subsides[16]. 
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5.2 Haemophilia in Arabic countries 
5.2.1 Health care in Arabic region 
Health care in Arabic countries is among the lowest levels worldwide. Although 
there are variations from country to country, in general the indicators of health care 
are low compared with western developed world. Many of these countries have now 
clear strategies towards an improved health care, but the expenditure on health is 
still low [63, 64].  
The health care financing in Arabic countries  is provided mainly from government 
revenues. The budgetary provision for the Ministries of Health has continued to 
increase (for example in Saudi Arabia from 2.8% of the national budget in 1970 to 5% 
in 2009). The remaining health services financing is derived from private sources (e.g. 
personal out-of pocket payments) and from occupational health insurance premiums 
mainly subscribed to by large private company employees[64]. Tables 4 and 5 shows 
the health expenditure and health indicators in Arabic countries. 
Table 4: Health expenditure among Arabic countries1 
Nr. Country GNI per capita in $ 
Total expenditure 
on health per 
capita $ 
Total expenditure 
on health as % of 
GDP 
1. Jordan 5,720 499 9.3 
2. Lebanon 11,750 1,054 8.1 
3. Sudan 1,920 161 7.3 
4. Djibouti 2,320 162 7.0 
5. Tunisia 7,460 524 6.2 
6. Algeria 7,890 544 5.8 
7. Yemen 2,220 142 5.6 
8. Morocco 4,190 251 5.5 
9. Saudi Arabia 24,500 1,150 5.0 
10. Egypt 5,470 282 5.0 
11. Bahrain 33,430 1,557 4.5 
12. Libia 16,270 709 3.9 
13. Iraq n.a 167 3.9 
14. Kuwait 53,480 1,498 3.3 
15. Oman 22,170 787 3.0 
16. Syria 4,490 138 2.9 
17. Emirates 45,660 1,756 2.8 
18. Somalia n.a 18 2.6 
19. Mauritania 1,990 47 2.5 
20. Qatar n.a 2,090 2.5 
1 Source: World Health Organization, Countries profiles, 2009 
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Table 5: Health status indicators in Arabic countries2 
Nr. Country 
Life 
expectancy at 
birth m/f
Healthy life 
expectancy at 
birth m/f
Probability of dying 
under 5 years per 
1000 population 
1. Emirates 77/79 64/64 7 
2. Qatar 78/79 67/64 9 
3. Bahrain 73/76 64/64 12 
4. Oman 72/77 63/65 12 
5. Lebanon 71/77 59/62 12 
6. Kuwait 78/79 67/67 13 
7. Syria 71/76 60/63 16 
8. Libia 70/75 62/65 19 
9. Tunisia 73/77 61/64 21 
10. Saudi Arabia 69/75 60/63 21 
11. Egypt 69/73 58/60 21 
12. Jordan 69/74 60/62 25 
13. Algeria 71/74 60/62 32 
14. Morocco 71/75 59/61 38 
15. Iraq 62/70 49/51 44 
16. Yemen 63/66 48/51 66 
17. Djibouti 58/62 43/43 94 
18. Sudan 59/59 47/50 108 
19. Mauritania 57/60 43/46 117 
20. Somalia 54/56 36/38 145 
5.2.2 Haemophilia care in Arabic world  
Haemophilia care in Arabic world shows variations from country to country. It 
varies from a good available care with presence of specialized haemophilia centers 
(e.g. Egypt, Jordan) to absence of care at all (e.g. Yemen, Somalia).  
In the Global Survey of WFH in 2009, 9702 cases of haemophilia were reported from 
13 Arabic countries [3, 9]. Of 22 countries of the Arab League, only 13 have at least 
one haemophilic center. Countries such Egypt, Algeria, Tunisia, Jordan and Syria 
have good organized programs and more than one haemophilia center. Other 
countries provide a relatively weak care compared to their financial resources; for 
example Saudi Arabia, with a population of about 24 million, and 326 reported cases 
of haemophilia has only one specialized care center for haemophiliacs[3]. 
Factor use also varies from country to country, according to economical level. High 
income countries consume large quantities; for example Saudi Arabia reported the 
highest use of factor concentrates in the region, about 191 736 IU per person with 
haemophilia A (PWHA)[25]. 
2Source: World Health Organization, Countries profiles, 2009 
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In other countries such as Yemen, Somalia, Djibouti, Mauritania, there is no 
specialized center and only little or no care for haemophiliacs is available. The major 
problems with regard to haemophilia care in those countries are[6]: 
• Lack of facilities for a proper laboratory diagnosis;
• Inadequate supply of safe factor concentrates.
The majority of population in such Arabic countries lives in rural area, under poor 
health care and where educational status is at the lowest levels with high illiteracy 
rate. Awareness and knowledge about the nature of the disease among patients and 
their families is low. Factor concentrates are available only in central hospitals, 
usually in the capital cities. Many haemophiliacs in villages have no access to factor 
concentrates and probably die from life threatening manifestations of the disease 
such as intracranial bleeding, before they reach the central clinics for a specialized 
treatment.  
Table 6:  Some indicators of haemophilia care among some Arabic countries3 
Nr. Country Population in 
thousands  
Estimated 
cases of 
haemophilia4 
Reported 
cases of 
haemophilia 
Number of 
Haemophilia 
centers 
1 Egypt 80,471 5,320 5,307 10 
2 Algeria 34,178 2,260 1,291 10 
3 Iraq 28.506 1,888 841 1 
4 Sudan 41,087 2,500 618 1 
5 Saudi Arabia 29,207 1,941 326 1 
6 Syria 22,198 1,290 300 2 
7 Tunisia 10.215 665 250 4 
8 Jordan 6,342 412 248 3 
9 Lebanon 4.055 266 165 1 
10 Palestine 4,013 266 131 6 
11 Qatar 833 56 112 2 
12 Oman 3,418 226 93 2 
13 Bahrain 739 50 20 1 
3Source: World Federation of Haemophilia, Global survey report, 2009 
4 These values were estimated according to prevalence rates used by WFH: Hemophilia A and B: 133 
per million male population 
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5.3 Haemophilia in Yemen 
5.3.1 Introduction to Yemen 
5.3.1.1 Geography and demography 
Figure 1: Political Map of Republic of Yemen5 
Republic of Yemen is located in Southwest Asia at the southern tip of the Arabian 
Peninsula between Oman and Saudi Arabia. It is situated at the entrance to the Bab-
el-Mandeb Strait, which links the Red Sea to the Indian Ocean (via the Gulf of Aden) 
and is one of the most active and strategic shipping lanes in the world. Yemen has an 
area of 555,000 square kilometers, including the islands of Perim at the southern end 
of the Red Sea and Socotra at the entrance to the Gulf of Aden. Yemen’s land 
boundaries total 1,746 kilometers. Yemen borders Saudi Arabia to the north and 
Oman to the northeast[65]. 
According to the latest census in 2008, the Republic of Yemen had a population of 
22.879.805 persons[66]. Yemen’s population has more than doubled since 1975 and 
has grown approximately 35 percent since the 1994 census, making Yemen the 
second most populous country on the Arabian Peninsula[64]. 
Population pyramid is with a wide base and about half of the population is under 15 
years old adding to the burden on the health sector for their special diseases 
management and protective programs. Population growth rate, at 3.02 percent per 
year is among the highest in the world, family planning activities are minimal, and 
the use of modern contraceptives is particularly low at 13 percent[64].The situation is 
compounded by the wide regional disparities and the significant differences between 
urban and rural conditions.  
The main demographic indicators are given in Table 7 and Figure 2. 
5 World Fact Book, Middle East, Yemen Profile, 2010 
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Table 7: Demographic indicators on Yemen6 
The indicator Values  Year of 
estimation 
Total population in thousands 22,198 2008 
Males population in thousands 11,826 2008 
Females population in thousands 10,372 2008 
% Urban population out of total 
population 
29 2008 
Crude birth rate per 1000 
population 
39.7 2006 
Crude death rate per 1000 
population 
9.0 2006 
% Population growth rate 3.0 2007 
% Population below 15 years 45.0 2007 
% Population 65 years and over 3.5 2007 
Total fertility rate (R) per woman 6.1 2006 
Figure 2: Composition of Yemeni population by age groups7 
6 Yemeni Ministry of Public Health and Population, Annual Report, 2009 
7 WHO, Eastern Mediterranean Regional Office, Yemen profile, September 2009 
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Figure 3:  Life expectancy at birth8 
Yemen’s population is predominantly Arab, but it also includes Afro-Arabs and 
South Asians. Arabic is the official language. English is also used in official and 
business circles. In the Mahra area (the extreme east), several non-Arabic languages 
(including Mehri) are spoken.  Virtually all citizens of Yemen are Muslims, either 
belonging to the Zaydi order of Shi'a Islam or to the Shafa'i order of Sunni Islam. 
There are also Jews, Christians and Hindus.  
5.3.1.2 Socio-economic status  
Yemen is one of the poorest countries in the Arab world and its economic fortunes 
depend mostly on oil. Most people are employed in agriculture and herding, 
services, construction, industry, and commerce account for less than one-fourth of 
the labor force. Unemployment rate is 15% and population below poverty line 34,8%.  
GDP is $26.6 billion, GDP - real growth rate is 3.9%, GNI - per capita is $1060 and 
labor force is 5.98 million[67]. 
5.3.1.3 Education 
Education indicators have improved during the last two decades but are still very 
low. The adult literacy rate is only 53 percent, and the gross enrollment ratio for basic 
education is 73 percent. Quality is widely acknowledged to be poor. The gender gap 
is among the widest in the world, with only 56 percent of primary school-aged girls 
in school, and much less freedom of female social and economic opportunity[64]. 
Some education indicators are given in Table 8. 
8 WHO, EMRO, Yemen profile, September 2009 
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Table 8: Education indicators among Yemeni population9 
Indicators Values in 
% 
Adult literacy rate 15+ years, total 53 
Adult literacy rate 15+ years, males 73 
Adult literacy rate 15+ years, females 31 
Gross primary school enrolment ratio - total 65 
Gross primary school enrolment ratio - male 73 
Gross primary school enrolment ratio - 
female 
56 
Gross secondary school enrolment ratio - 
total 
50 
Gross secondary school enrolment ratio - 
males 
69 
Gross secondary school enrolment ratio - 
females 
31 
5.3.1.3 Health care system 
The Yemen Health Care system represents about 95% of the total health care and 
services provided to the citizen with government finance to its prevention, medical 
and rehabilitation activities. Its structure is based on the health centers and units at 
the first touchline[66]. 
5.3.1.3.1 Public health care 
The health care system in Yemen consists of a large public sector with a sizable 
private sector. Public health care is organized in three levels: Primary Health Care 
(PHC) supported by secondary and tertiary referral care. PHC focuses on preventive 
health programs (immunization, Mother and Child Health (MCH) and family 
planning, health education, etc.) and provides first level curative care. It starts at the 
village level where PHC units are run by paramedical staff; the units are backed up 
by PHC centers, most of which are managed by one physician and have laboratory 
and X-ray facilities. Patients who cannot be properly managed at the PHC level are 
referred to rural, district or governorate hospitals (secondary care) for further 
diagnostic and curative treatment[66]. Some of these hospitals also provide support 
for national or regional immunization and disease control programs. Finally, tertiary 
hospitals provide specialized care and serve as teaching hospitals for the medical 
faculties of the country’s universities[64]. 
Tables 9, 10, 11 and 12 show some health indicators in Yemen. 
9 WHO, EMRO, Yemen profile, September 2009 
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Table 9:  Health expenditure indicators of Yemen10 
Indicator Value  Year 
GDP per capita US$ exchange rate 1,060 2008 
Total expenditure on health (per capita) US$ 
exchange rate 
41 2006 
Government expenditure on health (per capita) 
US$ exchange rate 
21 2006 
Total expenditure on health of % of GDP 4.5 2006 
General government expenditure on health as % 
of total health expenditure 
50.1 2006 
Out-of-pocket expenditure as % of total health 
expenditure 
47.5 2006 
General government expenditure on health as % 
of total government expenditure 
5.5 2006 
Ministry of health budget as % of government 
budget 
4.0 2006 
Table 10: Public Health facilities in Yemen11 
Facilities No 
Referral Hospitals 2 
General Hospitals 53 
District Hospital 182 
Health Center 793 
Health Units 2774 
Total Number of Health Facilities 3852 
Referral Hospitals Beds 1207 
General Hospitals Beds 8924 
District Hospitals Beds 4669 
Total Numbers of Beds 15184 
10Source: WHO, Countries profiles, Yemen, 2008 
11Source: Yemeni Ministry of Public Health and Population, 2009 
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Table 11:  Public Health Manpower12 
Categories No 
Physicians 6338 
Dentist 535 
Pharmacist 2336 
Nurses 12227 
Medical Assistants 2455 
Morshed/ Morshedah13 2801 
Technical Assistants 5729 
Others 11182 
Total 46331 
Table 12: Health facilities per 10000 of 
population 
Items No 
Hospitals 0.1 
Beds 7 
Physician 3 
Dentist 0.2 
Pharmacist 1 
Nurses 7.3 
Paramedical 10.2 
Health Centers &Units 2 
12 Source: Yemeni Ministry of Public Health and Population, 2009 
13Health Advisor  
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5.3.1.3.2 Private Health Care System (Modern, for-profit) 
The role of the private sector increasingly grows. It concentrated in the capital city 
and main cities of the governorates. The size of this sector indicates the availability of 
1336 doctors’ clinic, 615 foreign doctors and 309 foreign technicians[66].There is 
evidence of an expanding role for the private for –profit health sector in the delivery 
of health services. Although the exact number and scope of their activities are not yet 
known, it is likely that the coordination of investment and activities between the 
public and the private sectors will become an important issue in the coming 
years[64]. Table 13 gives some information about private health facilities in Yemen. 
Table 13:  Private Health facilities14 
Facilities No 
Hospitals 167 
Polyclinic 321 
Health centers 420 
Physicians clinic 1336 
Spec. clinics 838 
Dental clinic 654 
Dental Lab 155 
Laboratory 1189 
Radiology Clinic 224 
PHC 1355 
Midwifery 69 
Pharmacy 2681 
Drug Stores 2123 
These services are provided by the Non-governmental Organizations (NGO) local or 
international, religious or social. There are two local NGOs having wide health 
activities all over the country the first is the Yemen's Charity Society, which was 
launched and licensed in 1990. It had multiple agreements with the Ministry of 
Health, Social Fund for Development, international organizations, World Bank, and 
international NGOs for financing the health projects[64]. Their health facilities 
14 Source: Yemeni Ministry of Public Health and Population, 2009 
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cover13 out of 20 governorates and they have 11,500 employees serving population 
of 786,959. They have 5 hospitals (2 are specialized), 11 health centers, 3 dispensaries, 
and 1 health unit. All these facilities are equipped with the latest technology. They 
also have outreach activities and school health provision. The second is the Society of 
Family Care, which provides all the reproductive health services and mainly works 
in Sana’a[66]. 
5.3.1.3.3 Traditional 
Traditional medicine still plays an important role in Yemen. In many rural areas, it is 
the only medical assistance available to people, but it also competes with modern 
public and private health care which is either more expensive or regarded with 
suspicion. Medical practices are rooted in the Greco-Arabic tradition and have 
physical as well a spiritual dimension. Some of the more common procedures are 
cupping to draw off blood, cautery, bone setting and minor surgical techniques. In 
addition, local plant and animal products, some minerals and changes in dietary 
habits are used to treat ailments. Local birth attendants assist with deliveries and 
provide post-natal care. There are many aspects of traditional health care which are 
beneficial to individuals and the community, and which could complement modern 
medical practice. Traditional cures are often effective although they fail with most of 
the endemic diseases.  
5.3.1.3.4 Public /private interactions 
There is a private sector department at the MOPH with its policy and system but in 
reality it is only in papers and needs to be activated. There is a little interaction 
between the MOPH and the local NGO-s especially the Islah Social Charity Society, 
which implement some health projects with the MOPH. The interaction was based 
on competition with wide lack of coordination to improve the coverage and 
accessibility of health care services. The services were of low standards and there was 
poor management[68]. 
5.3.1.3.5 Health Insurance 
Currently the MOPH&P provide health insurance coverage only for the government 
employee. The private companies and organizations cover also their employees. The 
rest of population has no health insurance. The health insurance policies in Yemen 
are offered by private or nonprofit seeking organizations. At present, there are very 
few insurance companies in Yemen that offer insurance policies to both public and 
private organizations[66]. 
5.3.2 Epidemiology of Haemophilia in Yemen 
There are no official data about the prevalence of haemophilia in Yemen as there is 
no organized care strategy for this disease. The cases are not reported and even the 
major hospitals or the Ministry of Health have no registry or statistics regarding 
haemophilia patients. However, referred to the standard incidence used by WHO 
and WFH, Yemeni haematologists estimate that about 1460 people in Yemen are 
affected by haemophilia[69]. 
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Something that could be considered as specific for Yemen and Arabic countries in 
general, is the fact of consanguinity and marriage between the members of same 
large family15. This factor may probably increase the prevalence of this disease in this 
Arabic country. A haemophilia study was made among a large family in a province 
of Yemen. The pedigree was composed of 76 members, including 33 females and 43 
males. 27.2 % of the females were obligative carriers, each having at least one 
hemophilic son. 39.5 % of males were hemophilic, and among them 64.7 % died of 
hemophilia at age ranging from 20 days to 26 years, while the rest still live[70]. 
During my visit to the Branch of Blood Diseases at Thawra General Hospital in 
capital city, Sana’a, I found that during second half of year 2009, were treated 135 
cases of haemophilia. The age of patients varied between 11 months and 29 years. 
Most of cases were considered as severe according to the clotting factor assay.  
5.3.3 Ways of management, facilities, centres and clinics 
Republic of Yemen is the only country of Arabic peninsula without a specialized 
centre for haemophilia. Taking in consideration that Yemen is a poor developing 
country spending about 5,6 % of its GDP on the health care, the Ministry of Health 
concern is focused on the major health problems of the country, such as Infectious 
diseases16 and Malignancies.  As a result only a small or no attention is paid to rare 
diseases such as haemophilia.  
There are only two hospitals in the capital city, which offer treatment for Yemeni 
haemophiliacs. Thawra General Hospital and Republican Hospital are the two 
largest government hospitals in the country. In either of them, there is a branch of 
Haematology, at the Internal Medicine Department, dealing with haemophilia cases.  
Many cases are diagnosed accidentally during routine investigations done before 
surgical interventions or after circumcision. Usually, the new cases are diagnosed by 
haematologists or internists at their private clinics and then they are referred to the 
centres mentioned above. After the confirmation of the diagnosis, the patients are 
either admitted as stationary or treated as day ambulatory cases with factor 
concentrates. No unified protocol is used by haematologist, and each of them follows 
certain recommendations and protocols following the international literature and 
guidelines. Patients with complications are treated in other departments according to 
their conditions [71]. 
Until year 2000 there was no factor concentrates available, and the cases were either 
treated with FFP or DDAVP or referred outside the country for a better treatment. 
After an absence for two years (2007-2009), factor concentrates are again available in 
adequate amount. They are supposed to be offered free of charge by Ministry of 
Health, which supply only the two hospitals mentioned above[69, 70]. 
15Marriage between cousins in Arabic countries is a common old tradition  
16About 15000 people die annually from Malaria, which is endemic in many areas of Yemen 
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As no specialized centre is available, there is no comprehensive care and no 
educational program about the nature of the disease and its prophylaxis. Absence of 
genetic counseling and in-existence of facilities for early and prenatal diagnosis, are 
among the factors that help in the increase of number of haemophiliac individuals in 
Yemeni community[70]. 
Another challenge for haemophiliacs in Yemen is the large distance they have to 
cross, from their hometowns and villages until they reach the capital city. Most of the 
population lives in rural areas where no facilities are available. With a difficult 
mountainous terrain and a bad infrastructure, many of them have to travel more 
than 10 hours with their own cars, until they arrive in Sana’a. Under such conditions 
some of hemophiliacs with severe forms of the disease and life threatening 
complications have little chances to survive. 
Another treatment option is referring of cases outside the country. Some patients, 
who are capable to pay the high costs of such choice, choose other Arabic countries 
like Egypt or Jordan or even western countries, seeking for a better care. However, 
the poor majority of haemophiliacs do not have such a chance[69].  
5.3.4 Costs and financial resources  
Haemophilia is a complex health problem rather than only a deficiency of a single 
clotting factor. The impact and consequences of this disease affect significantly the 
socio-economic status of the community. For a proper care of a haemophilic patient, 
thousands of dollars are needed every year.  
In a country such Yemen, neither government nor the patient are able to pay for a 
proper management. The Yemeni Ministry of Health is supposed to provide factor 
concentrates free of charge for every haemophilic patient according to the need, but 
nothing more. In the absence of health insurance system, the patient should pay for 
every kind of intervention and management of subsequent complications. Even the 
services provided by government hospitals are not free.  
In Yemen, as in many other countries, the health services are under a severe financial 
strain which cannot be resolved with the present budgetary allocations. The actually 
available funds for health care provision are insufficient and the burden of obtaining 
adequate quality care is left to the individual patient, often at high cost [71]. 
In 1994, a cost sharing strategy has been introduced. Its objective was to secure 
sufficient funds through revenues from fees and charges for services in order to 
improve maintenance of facilities and supply of drugs, as well as the motivation and 
performance of health personnel. Cost sharing in Yemen depends on two types of 
charges. The first is fee for service, or user fees, for curative services. In Yemen, it is 
expected that user fees will contribute approximately 10-15% to overall running costs 
in government facilities. The second type of charge will be for essential drugs. The 
government will import low cost, good quality, generic essential drugs, and recover 
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100% of the costs for these basic essential drugs through client payments into a 
revolving drug fund[64, 66]. 
When patients do go to health facilities the cost is high, with on average $96.57 for an 
admission and $18.70 for an outpatient consultation. The average total cost for a 
hospital admission in government facilities is slightly lower than in private hospitals. 
This finding – contrary to common thought that private hospitals are much more 
expensive – is due to fact that cost linked to patients, required to buy drugs outside 
in private pharmacies. Outpatient consultancies in government facilities is cheaper 
($13.06) than in private health facilities ($24.33), but is considered by most 
respondents of poorer quality[64]. 
Under such conditions, without a health insurance, haemophilic patients face a big 
challenge on dealing with complications of the disease like transmitted infections or 
musculoskeletal complications.  
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5.4 Haemophilia in western European countries 
5.4.1 Health care in western European countries 
Health care in western European countries ranks among the highest levels 
worldwide. Such good care is a result of combination of adequate financial resources, 
presence of specialized centers and well trained medical staff. As shown on table 14, 
some European countries spent more than 10% of their GDP on health care, and this 
to high compared to Arabic countries[63]. 
Table 14: Health expenditure among some western European countries17 
Nr. Country GNI per capita 
in $ 
Total expenditure 
on health per 
capita $ 
Total expenditure 
on health as % of 
GDP 
1. Luxemburg 52,770 6,526 7.8 
2. UK 36,240 3,399 9.3 
3. Italy 30,800 3,027 9.5 
4. Finland 35,940 3,357 9.7 
5. Spain 30,830 3,150 9.7 
6. Norway 59,250 5,395 9.7 
7. Sweden 37,780 3,690 9.9 
8. Netherland 40,620 4,389 10.8 
9. Germany 35,950 4,129 11.3 
10. Switzerland 39,210 5,072 11.3 
11. France 33,280 3,943 11.7 
12. Belgium 35,380 4,237 11.8 
Life expectancy shows high levels, varying from country to country, between 77 - 80 
years for men, and 82-85 for women as shown in table 15.  Another important health 
indicator, probability of dying under 5 years, is very low compared to Arabic region. 
This indicator is up to 12 times higher in some Arabic countries, as an example, it is 
60 in Yemen, but only 4 in Germany[63]. 
Table 15 shows some health care indicators in some western European countries. 
17Source: Organization for Economic Cooperation and Development (OECD); World Health 
Organization, Countries profiles, 2009 
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5.4.2 Haemophilia care 
In year 2007 were reported 27,874 cases of Haemophilia A and 5,271 cases of 
Haemophilia B in European Union (EU) countries were reported[72]. 
Haemophilia care in western European countries is a well organized process 
providing a qualified management to all hemophiliacs, through the Haemophilia 
treatment centers (HTCs) which exist in all the EU Member States. Choice and levels 
of treatment, availability of comprehensive care and access to prophylaxis vary 
widely from one Member State to another [31]. 
In 2009, a questionnaire was circulated to 19 national haemophilia patient 
organizations in Europe affiliated to the European Haemophilia Consortium (EHC) 
and the World Federation of Hemophilia (WFH) to seek information about the 
organization of haemophilia care and treatment available at a national level. The 
responses received highlighted differences in the level of care despite the recent 
promulgation of consensus guidelines designed to standardize the care of 
haemophilia throughout the continent of Europe[73]. Table 16 shows the way of 
organization for haemophilia care in European countries. 
18Source: World Health Organization, Countries profiles, 2008 
Table 15: Some Health indicators among European countries18 
Country 
Life expectancy 
in years  at 
birth m/f 
Healthy life 
expectancy at 
birth m/f 
Probability of 
dying under 5 
years per 1000 
population 
Luxemburg 78/83 69/74 2 
Finland 77/83 69/74 3 
Italy 79/84 71/75 4 
Sweden 78/85 72/75 4 
Spain 78/84 70/75 4 
Norway 79/83 70/74 4 
Germany 78/83 70/74 4 
France 78/85 69/75 4 
Switzerland 80/84 71/75 4 
Netherland 78/83 70/73 5 
Belgium 77/83 69/73 5 
UK 78/82 69/72 5 
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Table 16: Central organization for haemophilia care19 
Country Has a general organization for 
haemophilia care 
Romania Yes 
Bosnia-Herzegovina No 
Bulgaria  No 
Lithuania Yes 
Latvia Yes 
Portugal No 
Russia Yes 
Switzerland No 
Poland Yes 
Slovakia Yes 
Belgium Yes 
France Yes 
Hungary Yes 
United Kingdom Yes 
Ireland Yes 
Germany No 
Sweden No 
Czech Republic Yes 
Netherlands  Yes 
There is a wide range in factor VIII consumption with usage ranging from 0.38 IU per 
capita in Romania to 8.7 IU per capita in Sweden (median: 3.6 IU per capita). Despite 
the specific inclusion of coagulation factor concentrate in the WHO list of essential 
medications, cryoprecipitate is still used in some eastern European countries[73]. 
The most significant advantage of haemophilia care in most of these countries is 
presence of the prophylactic treatment. Clinical studies show that the cost for 
treating haemophilia patients prophylactically is significantly higher than the cost of 
on-demand treatment; however, reducing the number of joint bleeds reduces other 
medical treatment costs and prevents disability in this population. Indeed, while 
analyses were not able to demonstrate significant differences with these other 
medical treatment costs, it is observed a trend that suggested hospital costs were 
lower for haemophilia patients treated prophylactically [39]. 
Table 17 shows that access to treatment for haemophilia patients in different 
European countries is different. 
19O’Mahony B, Haemophilia care in Europe: a survey of 19 countries, 2011 
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Table 17: Access to treatment for haemophilia patients in some European countries20 
Country Plasma Cryoprecipitate 
Plasma 
derived Factor 
Concentrates 
Recombinant 
Factor 
Concentrates 
Belgium Never Never Rarely Always 
Bosnia-Herzegovina Rarely Rarely Always Rarely 
Bulgaria Never Never Always Rarely 
Czech Republic Never Never Always Rarely 
France Never Never Always Always 
Germany Never Never Always Always 
Hungary Never Never Always Always 
Ireland Never Never Never Always 
Latvia Never Never Always Never 
Lithuania Rarely Rarely Always Rarely 
Netherlands  Rarely Never Always Always 
Poland Never Never Always Never 
Portugal Never Never Always Always 
Romania Always Rarely Rarely Rarely 
Russia Rarely Rarely Always Rarely 
Slovakia Never Never Always Rarely 
Sweden  Never Never Rarely Always 
Switzerland Never Never Rarely Always 
United Kingdom Never Never Rarely Always 
The expected annual cost (in the year 2000 prices) for a 30-year-old patient with 
average individual and treatment characteristics for on-demand EUR 51 832 and for 
prophylaxis EUR 146 118, was obtained from panel-data analysis of an 11-year 
retrospective panel of 156 patients with severe haemophilia in Norway and Sweden. 
Costs included haemophilia-related treatment costs within the health-care sector 
(factor concentrate, doctors’ visits, diagnostic procedures, hospitalization, invasive 
procedures, etc.) and cost for haemophilia-related resource use in other sectors [74]. 
Some haemophilia care indicators among some western European countries are 
given in the Table 18.   
20 O’Mahony B, Haemophilia care in Europe: a survey of 19 countries, 2011 
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Table 18:  Indicators of haemophilia care among some western European 
countries21 
Country 
Reported 
cases of 
haemophilia 
Haemophilia 
centers 
Reported use of 
factor 
concentrates 
VIII and IX 
Reported factor 
use per PWH 
Germany 4,320 32 770,000,000 178,240 
France 5,153 40 456,372,550 88,564 
UK 6,460 87 458,919,047 71,040 
Italy 3,270 52 350,000,000 107,033 
Sweden 1,020 3 95,422,000 93,550 
Netherlands 1,397 13 n.a n.a
Belgium 936 7 n.a n.a
Spain 1,985 38 230,080,500 115,909 
Norway 397 1 20,000,000 n.a
Finland 322 8 n.a n.a
Denmark 475 2 n.a n.a
Switzerland 672 11 35,000,000 52,083 
21Source: World Federation of Haemophilia, Annual Global Report, 2009 
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5.5 Haemophilia in Germany 
5.5.1 Introduction to Germany 
5.5.1.1 Geography and demography 
Figure 4: Map of Federal Republic of Germany22 
The Federal Republic of Germany is a country in Central Europe, stretching from 
Alps to the North Sea, with a territory of 357,021 km2, consisting of 349,223 km2 of 
land and 7,798 km2 of water[75]. Germany has the second largest population in 
Europe and the seventh largest area, sharing borders with nine European countries: 
Denmark, Poland, Czech Republic, Austria, Switzerland, France, Belgium, 
Luxembourg and Holland.  
According to the official statistics, Germany has about 82,218,000 inhabitants which 
correspond to a population density of 230 persons per square kilometer[76]. 
Table 19:  German Population and its gender distribution23 
Specification 2005 2006 2007 
Total 82,438.0 82,314.9 82,217.8 
Male 40,340.0 40,301.2 40,274.3 
Female 42,098.0 42,013.7 41,945.5 
22 Source: CIA Fact Book, Germany profile, 2011 
23Source: German Federal Statistical Office, 2010 
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Table 20:  Live births and deaths among German population24 
Specifications 2007 2008 2009 
Live births 684,862 682,514 665,126 
Per 1 000 inhabitants 8.3 8.3 8.1 
Deaths 827,155 844,439 854,544 
Per 1 000 inhabitants 10.1 10.3 10.4 
5.5.1.2 Economy 
Germany has the largest national economy in Europe, and the fifth largest GDP in 
the World[75]. Exports account more than one-third of national input. Germany is 
the second largest exporter in the World[77]. 
GDP is $ 3,330 billion, GNI - per capita is $ 42,450 and labor force is 43.51 million. 
The service sector contributes around 70% of the total GDP, industry 29,1% and 
agriculture 0,9%. Most of country’s products are in engineering, especially in 
automobiles, machinery, metals, and chemicals[77]. 
5.5.1.3 Health care system 
Federal Republic of Germany has a modern and efficient health care system that 
ensures its citizens the provision of high-quality care. The roots of the German health 
system date back to 1883, when nationwide health insurance became compulsory. 
Today’s system is based on social health insurance and characterized by three co-
existing schemes. In 2003, about 87% of the population were covered by statutory 
health insurance; based on income, membership was mandatory for about 77% and 
voluntary for 10%. An additional 10% of the population took out private health 
insurance; 2% were covered by governmental schemes and 0.2% were not covered by 
any third-party-payer scheme[78, 79]. 
Nearly 2,200 hospitals and more than 300,000 doctors care for upwards of 72 million 
members of the statutory and 8.5 million members of the private health insurance. At 
the same time, an increasing number of people are finding work in the health care 
system, their current number standing at about 4.3 million. Since 1999, this workforce 
has increased by approx. 200,000 in spite of the difficult economic situation[80]. 
Annual health care expenditure amounts to 11,3 % of the gross domestic product. 
Being the largest European market, Germany is a highly attractive location for the 
pharmaceutical industry, medical technology and biotechnology. The German health 
care system is markedly less regulated than most of its counterparts throughout 
Europe, so that innovative products make it to market very quickly. In 2005 alone, 
24 Source: German Federal Statistical Office, 2010 
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we saw more than 3,000 new patents in the medical sector. Germany is second only 
to the USA among world market leaders in the field of medical technology[78, 80]. 
5.5.2 Haemophilia Care in Germany 
According to last Global Survey of World Federation of Haemophilia (WFH) there 
are about 4320 people affected by haemophilia in Germany[3]. 
In Germany, people with haemophilia are entitled to a choice of all treatments 
ranging from an optimal level of factor replacement therapy on demand as well as on 
a prophylactic basis for those who need it, to comprehensive care at a Haemophilia 
Treatment Centre. All these measures are cost effective as they help secure a high 
quality of life through lowering the risk of disability, thus reducing direct costs for 
management of damaged joints and extensive care for a disabled person, as well as 
indirect costs through loss of workforce[81]. 
Haemophilia care in Germany is provided through 12 specialized Haemophilia 
Treatment Centers. Apart from treatment and care at the HTCs, specialized 
physicians in practices and at haematology units in general hospitals provide care. 
Home treatment is available for children as well as for a number of people suffering 
from severe haemophilia[72]. 
Germany stand out for using a huge amount of FVIII IUs per PWHA (person with 
hemophilia A), about 114 333 IU per PWHA [25]. About half of the factor 
concentrates used in Germany are recombinant clotting factors and the other half are 
human plasma-derived concentrates, with the average number of units of factor VIII 
concentrate used per capita being 5.9 IU. About 90% of children and 40% of adult 
people with haemophilia in Germany receive prophylactic treatment[81]. 
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6  The empirical study 
6.1 Study design 
The empirical study is divided in two parts. The first part is based on data and chart 
abstraction analysis collected through interviews of haemophilic patients from 
Haematology Department at Thawra General Hospital in Sana’a, Yemen. Thawra 
General Hospital is the largest referral hospital in the country with a capacity of 900 
beds[66]. Demographic data, diagnosis, treatment modality, complications of 
haemophilia and cost of treatment, were collected and discussed in a retrospective 
analytical study. In the second part, were analyzed the data obtained from European 
Study in Clinical, Health Economic and Quality of Life (ESCHQoL) regarding the 
haemophilic patients in Germany.  European Study in Clinical, Health Economic and 
Quality of Life outcomes in Haemophilia treatment is a study funded by European 
Commission and applied to 1400 haemophiliacs in 21 European countries between 
2004 and 2006. 
6.2 Methods  
The theoretical part is based on: 
• Literature research including original grey and peer reviewed articles
regarding epidemiology, diagnosis and management of haemophilia. 
• Interviews of Yemeni haematologists and WFH representatives for Arabic
region regarding the haemophilia care in Yemen and other Arabic countries. 
• Web based research.
The empirical part is based on data collection and descriptive data analysis. 
6.3 Patients  
This study was focused on Yemeni and German patients affected with Haemophilia 
A or Haemophilia B. Only cases with severe form of the disease took part.  
6.4 Data sources and survey instruments 
In addition to direct interviews of haemophilic patients, medical records and files 
provided by Hematology Department at Thawra General Hospital in Sana’a were 
used as data sources for this study. The ESCHQoL questionnaire survey was applied 
to all Yemeni patients who took part in this study. Data of German patients are 
obtained from ESCHQoL program with the permission of its authorities. The data 
and information obtained from questionnaire were analyzed through Microsoft 
EXCEL 2010 program. The questionnaire sample applied in this study is given in the 
appendix. 
6.5 Data collection and interpretation 
Data collection was a part of a study which took place between Munich and Sana’a 
during a period of time from 01.07.2009 to 01.12.2010. Two separate visits to Thawra 
General Hospital and other private clinics in Sana’a were focused on collection of all 
necessary data and information about situation of Yemeni haemophilic patients and 
care provided to them in the last 6 months. The Yemeni patients were collected 
according to their clinical presentation and laboratory findings. The German patients 
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were matched to Yemeni haemophiliacs, regarding their age and severity of disease. 
The data were interpreted on the light of recommendations and advices given from 
experienced haematologists at Thawra General Hospital and Republican Hospital in 
Sana’a. The Yemeni patients were collected according to their clinical presentation 
and laboratory findings. The German patients were matched to Yemeni 
haemophiliacs, regarding their age and severity of the disease.  
6.6 Results 
6.6.1 Yemen 
6.6.1.1 Case collection 
During my visit in the Haematology Department at Thawra Hospital in Sana’a we 
interviewed 20 severe cases of haemophilia. I collected them from a total number of 
39 patients who were seeking for medical care in the Haematology Department. The 
rest of patients (19 patients) were mild or moderate haemophiliacs. The age of 
patients varied from 1 to 29 years and the majority of them were below 18 years with 
a mean age of 11, 6 years. Haemophilia A and Haemophilia B cases were distributed 
with a proportion of 80% to 20% of total cases, respectively. The general 
characteristics of patients are given in Table 21. A more detailed table is given in the 
appendix. 
Table 21: General characteristics of  Yemeni haemophiliacs 
Total number of patients 20 
      Severe cases 20 
     Mild and moderate  cases 0 
Age 
      Min-Maximal 1 year - 29 years 
      Mean 11.6 years 
      Median 9 years 
Type of Haemophilia 
(severe cases) 
      A 16 cases 
      B 4   cases 
The majority of cases were children, 35% of them preschooler. About 40% of patients 
were pupils in the primary school and 20% attended or still attend the high school. 
One patient has completed the university studies. None of the adults was able to 
work at time of interview. 
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Figure 5: Educational level among Yemeni haemophilic patients 
About 70 % of patients came from rural areas. No one of them had a health insurance. 
Figure 6: Age group distribution among Yemeni patients 
6.6.1.2 Clinical manifestations 
Age at first bleeding varied from 1week to 10 months. In 45% of cases the bleeding 
occurred during circumcision, a religious ritual among Muslims, done mostly within 
the first 2 weeks of life.  
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Figure 7: First bleeding site among Yemeni haemophiliacs 
First joint bleeding occurred at ages between 6 and 10 months. The most affected 
joint was the knee followed by ankle and wrist joint. The frequency of joint affection 
is given in Figure 8. 
Figure 8: Frequency of joint bleeding among Yemeni haemophiliacs 
Regarding other clinical manifestations rather than joint bleeding, 14 patients have 
had a muscle haematoma during the last 6 months. Two brothers had spontaneous 
intracranial bleeding, 5 cases had a gastrointestinal manifestation and 3 cases had a 
genitourinary bleeding in the last 6 months.  
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Figure 9: Clinical presentation during last 6 months 
6.6.1.3 Concomitant diseases and complications 
About 40% of cases were documented to be anaemic. Concerning chronic diseases, 
no case was known to be affected by hepatitis, malignancies, AIDS or other diseases. 
No case of pseudotumor formation or fracture was reported. As no laboratory 
facilities for detection and diagnosis of immunological reactions are available in 
Yemen, no one knows about the incidence of inhibitor formation among patients 
who receive factor concentrates as treatment.  
6.6.1.4 Treatment modality 
No case was treated prophylactically, as there is no such a strategy in Yemen. All 
patients were treated on demand at haematological clinic, and no one was on home 
treatment. First infusion age varied from 2 weeks to 10 months, with an average 
value of 3 months.  
Figure 10: Treatment modality in last 6 months 
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During the last 6 month period, factor concentrates were given to only 65% of 
patients. In total, an amount of 15,050 units of factor concentrates were consumed. 
Other cases were treated with FFP or Cryoprecipitate. There was no use of 
recombinant factor concentrates, DDAVP or any other drug.  
6.6.1.5 Cost of treatment 
The cost of treatment was relative high, considering the economical level of Yemeni 
patients. During the last 6 months, the Yemeni haemophiliacs spent much more than 
their annual income. The costs varied from EUR 200 to EUR 2000, with an average of 
865 Euro per patient, including costs of investigations, treatment and follow up, 
hospitalisation and travel for those coming from outside the capital city.  
Figure 11: Cost of treatment in last 6 months 
The MOPH is supposed to supply factor concentrates free of charge for all patients 
with severe form of disease. However, the majority of patients pay much money in 
order to have the needed treatment.  
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6.6.2 Germany 
6.6.2.1 Case collection 
Regarding German haemophiliacs, we analyzed the clinical data of 40 severe affected 
cases, obtained from ESCHQoL program. As the ESCHQoL program includes also 
haemophiliacs from other European countries including old patients up to 88 years, 
we have collected only those German severe affected cases of haemophilia who 
match the Yemeni haemophiliacs regarding their ages. The age of collected patients 
varied from 3 years to 29 years with a mean of 12.7 years.  Haemophilia A and 
Hemophilia B cases were distributed with a proportion of 80% to 20% of total cases, 
respectively.  
The general characteristics of patients are given in Table 22. A detailed table is given 
in the appendix.  
Table 22:  General characteristics of  German haemophiliacs 
Total number of patients 40 
      Severe cases 40 
     Mild and moderate  cases 0 
Age 
      Min-Maximal 3years - 29 years 
      Mean 12.7 years 
      Median 10 years 
Type of Haemophilia 
      A 32 cases 
      B 8  cases 
6.6.2.2 Clinical manifestations 
Age at first bleeding varied from 0 to 39 months, with an average of 10 months. The 
first bleeding site was mainly a joint bleed. The number of bleedings in the last 6 
months varied from 0 to 12 with an average of 2.5 bleeds. The most affected joint was 
knee followed by ankle, as shown in Figure 13. 
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Figure 12: Frequency of joint bleeding in German patients 
Regarding other clinical manifestations rather than joint bleeding, only one patient 
has had an intracranial bleeding (ICB) during the last 6 months. The clinical 
manifestations among German haemophiliacs during last 6 months are shown in 
Figure 14. 
Figure 13: Clinical manifestations among German haemophiliacs 
6.6.2.3 Concomitant diseases and complications 
Concerning chronic diseases, one case was affected by hepatitis C virus (HCV), 2 
cases with HIV, one case with joint atrophy and one case was complicated with 
anaemia. 
37,5
7,5 5 2,5
0
10
20
30
40
50
60
70
80
90
100
Joint 
bleeding
GIT 
bleeding
Hematuria ICB
C
as
es
 in
 %
Clinical manifestation
51 
Figure 14: Complicated German cases 
Five cases developed inhibitors during therapy with factor concentrates. They 
represented 12.5% of total cases.  
6.6.2.4 Treatment modality 
All cases were on prophylactic treatment, most of them with secondary prophylaxis, 
and almost all of them, except one case, receive home treatment. 
Figure 15: Type of prophylaxis provided to German haemophiliacs 
During the last 6 months period, factor concentrates were given to all of 40 patients. 
In total, an amount of 4,009,770 IU of factor concentrates were consumed during the 
last 6 months with a mean of 100,244 IU per patient. The majority of cases, as shown 
in Figure 17, were treated by recombinant factor concentrates. No case was treated 
with FFP, Cryoprecipitate or DDAVP.  
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Figure 16: Type of factor concentrates used during last 6 months 
6.6.2.5 Costs 
Regarding German haemophiliacs, the cost of care was covered almost 100% from 
the health insurance.  
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6.7 Discussion 
Haemophilia is a group of X-linked bleeding disorders affecting a considerable 
number of world populations. Highly purified concentrates are now available for 
treatment and are considered safe and effective. The main complication of treatment 
is the development of antibody inhibitors against either factor VIII or factor IX [1, 2]. 
The WFH estimates that 75% of people with haemophilia in the world do not receive 
adequate care [4].In developed countries, early treatment of bleeding episodes and 
home therapy quickly evolved as the primary management option. Presence of 
specialized centres, training and education of patients to achieve comprehensive 
haemophilia care are the main advantages of the comprehensive treatment concept in 
developed countries. This is not the case in most developing countries where the 
government does not have the resources to buy the necessary quantities of 
coagulation factors in the face of more urgent health priorities and hardly any 
patients can afford to pay for their own treatment even for on-demand home therapy. 
The main problems are insufficient supply with clotting factor concentrates, lack of 
access to these concentrates and absence of specialized care centres [6].  
The Arabic region includes 22 member countries of Arab League. The Arab League is 
rich in natural resources, with enormous oil and natural gas resources in certain 
member states. Economic development in the Arab League is very disparate. 
Significant difference in wealth and economic conditions exist between the rich oil 
states like UAE, Qatar, Kuwait, on the one hand, and poor countries like Yemen, 
Mauritania and Djibouti on the other.  
The health care provided to community, a part of which is the haemophilia care, also 
shows variations from country to country depending on economical level.  In the 
Global Survey of WFH in 2009, 9702 cases of haemophilia were reported from 13 
Arabic countries [3, 9]. Of 22 countries of the Arab League, only 13 have reported at 
least one haemophilic center. Countries such Egypt, Algeria, Tunisia, Jordan and 
Syria have good organized programs and more than one haemophilia center. Other 
countries provide a relatively weak care compared to their financial resources; for 
example Saudi Arabia, with a population of about 24 million, and 326 reported cases 
of haemophilia has only one specialized care center for haemophiliacs [3]. Factor use 
also varies from country to country, according to economical level. High income 
countries consume large quantities; for example Saudi Arabia reported the highest 
use of factor concentrates in the region, about 191 736 IU per PWHA [25]. 
Yemen is one of the poorest countries in the Arab world and its economic fortunes 
depend mostly on oil [67]. It is the only country of Arabic peninsula without a 
specialized centre for haemophilia. Taking in consideration that Yemen is a poor 
developing country spending about 5,6 % of its GDP on the health care, the Ministry 
of Health concern is focused on the major health problems of the country, such as 
infectious diseases and malignancies.  As a result only a little or no attention is paid 
to rare diseases such as haemophilia. There are only two hospitals in the capital city, 
which offer treatment for Yemeni haemophiliacs. Thawra General Hospital and 
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Republican Hospital are the two largest government hospitals in the country. In 
either of them, there is a branch of Haematology, at the Internal Medicine 
Department, dealing with haemophilia cases [69].  
As Yemen is a country with a large area, about 555,000 km2, and most of population 
live in rural area, haemophiliacs have to cross hundreds of miles in order to seek for 
some care in the capital city, Sana’a. With a difficult mountainous terrain and a bad 
infrastructure, many of them have to travel more than 10 hours with their own cars, 
until they arrive in Sana’a. Under such conditions some of haemophiliacs with severe 
forms of the disease and life threatening complications have little chances to 
survive[71].   
In contrast to Arabic region, haemophilia care in western European countries is a 
well organized process providing a qualified management to all haemophiliacs, 
through the Haemophilia treatment centers (HTCs) which exist in all EU Member 
States. Choice and levels of treatment, availability of comprehensive care and access 
to prophylaxis vary widely from one Member State to another [31]. 
In Germany, people with haemophilia are entitled to a choice of all treatments 
ranging from an optimal level of factor replacement therapy on demand as well as on 
a prophylactic basis for those who need it, to comprehensive care at a Haemophilia 
Treatment Centre [81]. Haemophilia care in Germany is provided through 12 
specialized Haemophilia Treatment Centers. Apart from treatment and care at the 
HTCs, specialized physicians in practices and at haematology units in general 
hospitals provide care. Home treatment is available for children as well as for a 
number of people suffering from severe haemophilia[72].    
Germany stand out for using a huge amount of FVIII IUs, about 114 333 IU per 
PWHA [25]. About half of the factor concentrates used in Germany are recombinant 
clotting factors and the other half are human plasma-derived concentrates, with the 
average number of units of factor VIII concentrate used per capita being 5.9 IU. 
About 90% of children and 40% of adult people with haemophilia in Germany 
receive prophylactic treatment [81].  
Regarding results of the empirical study, the peak age among Yemeni haemophiliacs 
who participated in this study was 29 years. This fact should be attributed to two 
major reasons; first and most important is the fact that due to absence of care in the 
last few decades the patients couldn’t survive and eventually died before they reach 
their 30’s as a result of life threatening conditions and complications. The other 
reason is that the majority of patients with mild and moderate form of the disease do 
not seek for medical care, even if they have bleeding episodes. The Yemeni 
haematologists reported that they didn’t find any patient older than 30 years[71].  
In the majority of Yemeni haemophiliacs, the first bleed occurred during 
circumcision within first 2 weeks of life, which, in many cases if not mainly, is 
performed at home by a nurse. In such conditions, many newborns with very low 
levels of factor VIII or IX face continuous bleeding and probably die. Education and 
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awareness about the nature of this disease could play an important role in preventing 
such induced life threatening bleedings.   
Currently no Yemeni patient is treated prophylactically as there is no such strategy in 
Yemen. The minimal care provided to severe cases is based still on FFP, 
Cryoprecipitate, DDAVP and even whole blood transfusions. The amount of factor 
concentrates used by only some severe cases with life threatening manifestations, 
such as ICB, is very low. According to our observation, the total amount of factor 
concentrates administered by 13 patients during the last 6 months was 15,050 IU, 
with an average of 1,157 IU per patient. Compared to Yemeni haemophiliacs, a 
German patient received 100,224 IU or about 90 times more factor concentrates, in 
addition to a good organized care with a prophylaxis program.  
In Germany, the health care costs for haemophilic patients, including cost of factor 
replacement, were almost 100% covered by health insurance. As we mentioned in 
chapter 5, the majority of Yemeni population do not have a health insurance. As a 
result all patients, including those affected by haemophilia, should pay for every 
kind of care and medical procedure. The majority of haemophiliacs are not able to 
cover the high cost of factor concentrates, which is supposed to be covered by Ministry 
of Health. The cost of care among Yemeni haemophilic patients during last 6 months 
varied from EUR 200 EURO to EUR 2000, with an average of EUR 865 per patient. 
These amounts of money, which are modest in our vision, exceed the average of 
annual income among Yemeni population. It should be mentioned that access to 
factor concentrate even for severely affected Yemeni haemophiliacs is impossible[69]. 
As it is shown in this analysis, there is a huge difference regarding the haemophilia 
care provided in both regions, particularly between Yemen and Germany. The fact 
that other Arabic countries such as Saudi Arabia, Oman, UAE have huge financial 
resources and a good organized haemophilia care, is an evidence that Yemen is 
totally isolated and abandoned from its Arab neighbors regarding this problem.  
In Yemen, as in other developing countries, the major problems with regard to 
haemophilia care are: absence of haemophilia centers; inadequate supply of safe 
factor concentrates, lack of awareness and education about the nature of the 
disease[6]. 
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6.8 Recommendations 
After the analysis of current situation of haemophiliacs in Yemen and care provided 
to them, we consider that application of the following recommendations will 
improve the haemophilia care in this country: 
• Initiation of a first step for a Haemophilia Center in Sana’a, as a result of
coordination between Yemeni authorities and WFH representative for Arabic
Region
• Stimulation of a humanitarian financial support, from rich Arabic neighbor
countries, to found an initial center for haemophiliacs in capital city Sana’a.
• Formulation of educational guidelines for haemophiliacs about the nature of
the disease
• Organization of a national network and creation of a registry for
haemophiliacs
• Home therapy (living far away from capital city, Yemeni haemophiliacs have
to cross hundreds of miles to seek for some care)
• A twinning program between haemophilia centers in Germany and clinics
dealing with haemophilia in Yemen.
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8. APPENDIX
8.1 Clinical data of German patients 
Nr Age 
in 
years 
Type of 
Hemophilia 
Age in 
months 
at first  
bleeding 
No of 
bleedings 
in last 6 
months 
Prophylaxis Home 
Treatment 
Type of 
factor 
concentrates 
Amount 
of factor 
used in 
the last 
6 
months 
in IU 
Other 
medications 
1 3 A 0 2 Yes Yes Recombinant 68,250 
2 3 A 13 5 Yes yes Recombinant 39,780 
3 4 A 12 2 Yes no Recombinant 49,000 
4 4 A 2 0 yes Yes 
Plasma 
derived 72,000 
5 4 A 3 4 Yes Yes Recombinant 126 
6 5 A 14 0 Yes Yes Recombinant 51,000 
7 5 A 8 0 Yes Yes 
Plasma 
derived 79,000 
8 5 A 12 1 Yes Yes Recombinant 72,000 
9 6 A 2 4 Yes Yes Recombinant 76,000 
10 6 A 17 2 Yes Yes Recombinant 78,000 
11 7 A 12 5 Yes Yes 
Plasma 
derived 94,000 
12 7 A 5 0 Yes Yes Recombinant 97,500 
13 8 A 13 1 Yes Yes Recombinant 78,000 
14 8 A 39 3 Yes Yes 
Plasma 
derived 63,000 
15 8 B 9 2 Yes Yes Recombinant 72,000 
16 8 B 11 1 Yes Yes 
Plasma 
derived 392,000 
17 9 B 0 1 Yes Yes 
Plasma 
derived 273,000 
18 9 A 3 1 Yes Yes 
Plasma 
derived 83,000 
19 9 B 0 3 Yes Yes 
Plasma 
derived 266,400 
20 10 B 9 2 Yes Yes 
Plasma 
derived 48,000 
21 10 A 1 5 Yes Yes FEIBA 180 
22 11 A 22 4 Yes Yes 
Plasma 
derived 144,000 
23 11 A 11 2 Yes Yes 
Plasma 
derived 72,000 
24 13 A 3 1 Yes Yes 
Plasma 
derived 52,000 
25 13 A 10 1 Yes Yes Recombinant 146,000 
26 14 B 10 11 Yes Yes Recombinant 88,000 
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27 16 A 14 1 Yes Yes 
Plasma 
derived 153,000 
28 16 A 1 5 Yes Yes Recombinant 110,000 
29 17 A 10 3 Yes Yes Recombinant 68,000 
30 17 A 12 0 Yes Yes Recombinant 112,000 
31 20 A 14 1 Yes Yes Recombinant 78,000 
32 20 A 24 1 Yes Yes 
Plasma 
derived 190 
33 21 B 10 2 Yes Yes 
Plasma 
derived 72,000 
34 21 A 5 0 Yes Yes 
Plasma 
derived 98,000 
35 25 A 16 4 No Yes Recombinant 80,000 
36 25 A 6 12 Yes Yes Recombinant 156,000 
37 27 B 12 3 Yes Yes 
Plasma 
derived 30,000 
38 27 A 6 10 Yes Yes Recombinant 85,000 
39 29 A 6 2 Yes Yes Recombinant 190,000 
40 29 A 12 2 Yes Yes Recombinant 78,000 
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 8.2 Clinical data of Yemeni patients 
Nr 
Age 
in 
years 
Type of 
Hemophilia 
Age in 
months 
at first  
bleeding 
No of 
bleedings 
in last 6 
months Prophylaxis 
Home 
Treatment 
Type of 
factor 
concentrates 
Amount 
of factor 
used in 
the last 
6 
months 
in IU 
Other 
medications 
1 
1 A 1 12 No No 
Plasma 
derived 1,200 
2 
1 B 8 15 No No 
Plasma 
derived 1,400 
3 1.5 A 0.5 10 No No 0 FFP 
4 2 A 10 8 No No 
Plasma 
derived 500 
5 3 A 9 12 No No 
Plasma 
derived 1,250 
6 4 A 1 8 No No 0 FFP 
7 7 A 4 5 No No 0 Cryoprecipitate 
8 8 B 0.25 10 No No 
Plasma 
derived 750 
9 8 A 1 7 No No 0 FFP 
10 9 A 1 11 No No 
Plasma 
derived 1,000 
11 9 A 1 10 No No 
Plasma 
derived 900 
12 10 A 6 9 No No 0 Cryoprecipitate 
13 13 A 6 17 No No 
Plasma 
derived 1,800 
14 16 A 0.5 6 No No 0 Cryoprecipitate 
15 18 A 3 9 No No 0 FFP 
16 20 B 6 21 No No 
Plasma 
derived 2,500 
17 21 B 8 18 No No 
Plasma 
derived 1,500 
18 25 A 0.5 12 No No 
Plasma 
derived 1,000 
19 27 A 7 7 No No 
Plasma 
derived 750 
20 29 A 2 6 No No 
Plasma 
derived 500 
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8.3 ESCHQoL Questionnaire sample 
 
 
  Page 1 
Patient initials Centre number Patient number 
ESCHQOL Study 
Medical Documentation Form 
SECTION - 1 
Demographics 
ESCHQoL Med Doc 
Patient initials (to fill in on the top of each section)
First 2 letter of the name First 2 letter of the surname 
Patient birthdate 
Country of birth 
DD MM YY 
Weight (Kg) . Height (cm) 
Smoker: NO Ex-smoker YES 
If Yes no. of cigarettes per day 
Haemophilia A B 
Factor VIII or IX level < 1% : YES NO 
if No specify % 
Education Low/middle school degree Pre-Scolar 
High/technichal school degree Student / Pupil 
University degree 
Post-degree diploma/PhD 
Employment 
Student 
Houseman/wife 
Unemployed 
Military/Civil service 
Clerk full time part time no. hours/week 
Blue collar full time part time no. hours/week 
White collar full time part time no. hours/week 
Shop keeper 
Professional 
Executive/Manager 
Enterpreneur 
Retirement pensioner 
Early pensioner for haemophilia 
Early pensioner for other reasons specify 
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  Page 2 
Patient initials Centre number Patient number 
ESCHQoL Med Doc 
SECTION - 2 
Bleeding history 
A. Age at first bleeding episode requiring treatment: months 
B. Age at first joint bleeding episode: months 
C. Total number of bleeding events in the previous 6 months 
C.1. Out of these events, how many were joints bleeding events 
D. There are target joints? NO YES 
(Definition: 3 or more bleeds in the same joint in the previous 6 months) 
IF YES: D.1. Number of target joints: 
D.2. Sites: ankle R L 
elbow R L 
knee R 
other, specify 
E. Has an iliopsoas haematoma ever occurred ? NO  YES 
If yes, did it occur in the past 6 months? NO  YES 
F. Has a gastrointestinal bleeding ever occurred ? NO  YES 
If yes, did it occur in the past 6 months? NO  YES 
G. Has a cerebral bleeding ever occurred ? NO  YES 
If yes, did it occur in the past 6 months? NO  YES 
H. Has a genitourinary bleeding ever occurred ? NO  YES 
If yes, did it occur in the past 6 months? NO  YES 
I. Has a pseudotumor/haemorrhagic cyst 
ever occurred ? 
NO  YES 
If yes, did it occur in the past 6 months? NO  YES 
J. Has an haematoma ever been complicated NO  YES 
with infection or compartimental syndrome? 
If yes, did it occur in the past 6 months? NO  YES 
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  Page 3 
Patient initials Centre number Patient number 
ESCHQoL Med Doc 
SECTION - 3 
Inhibitor history 
Past or present history of inhibitor development Yes No 
IF NO : GO TO THE NEXT SECTION 
IF YES : A. Age at inhibitor development: 
months 
B. Historical peak titre: 
BU/ml 
C. Is the inhibitor still present? No 
Yes 
IF YES : C.1. last titre: 
BU/ml 
C.2. Usual treatment of bleedings events: 
HIGH DOSE FVIII 
RFVIIa 
APCC/FEIBA 
PCC 
D. Has the patient undergone immunotolerance treatment? 
No Yes 
If Yes, was it successful? Yes 
No 
still on immune tolerance 
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E. Anemia: *N.A. YES  If Yes: light (10-12 g/dl) NO 
moderate (8-10 g/dl) 
severe (6-8 g/dl) 
very severe (<6 g/dl) 
F. Dental disorders: *N.A. YES  If Yes: caries NO 
parodontitis 
infections(abcess, osteitis) 
partial edentition 
total edentition 
 
  Page 4 
Patient initials Centre number Patient number 
SECTION - 4 
Concomitant diseases 
ESCHQoL Med Doc 
(Definition: diseases that have required in the past 6 months regular visits or treatment) 
A. Other known bleeding abnormalities *N.A. YES NO 
If Yes, specify: 
B. Malignancy YES NO 
If Yes, specify: 
C. Chronic viral infection: *N.A. YES NO 
If Yes: 
hepatitis B 
virus(HBs Ag+) 
hepatitis delta
virus(delta Ag+)
hepatitis C 
virus(PCR+) 
no signs or symptoms of advanced liver disease 
PT ratio > 2.0 
low serum albumin (< 3 g/dl) 
portal hypertension (US scan) 
cirrhosis 
oesophageal varices 
ascites 
encephalopathy 
Treatment with IFN/Ribavirine/lamivudine: NO finished current 
D. HIV infection: YES If Yes:  asymptomatic NO 
minor HIV-related signs 
full blown AIDS 
CD4 cell counts >500/cmm 200-500/cmm <200/cmm 
Treatment: NO with 1-2 drugs with 3 or more drugs 
G. Abuse of recreational drugs: *N.A. YES If Yes:  alcohol NO 
opiate 
non-opiate 
H. Other diseases: *N.A. YES NO 
if Yes specify : 
*Not Available
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  Page 5 
Patient initials Centre number Patient number 
ESCHQoL Med Doc 
SECTION - 5 
Surgery 
A. Orthopaedic surgery: [in the past 6 months] NO YES 
Sites: 
radiation synovioorthesis 
arthroscopic synovectomy 
synovectomy (surgical) 
arthrodesis 
arthroplasty 
tenotomy 
wedge-osteotomy 
excision of cysts 
excision of orthopedic material etc. 
fracture 
others:  
B. Dental procedures: [in the past 6 months] NO YES 
Type (Specify): 1. 
2. 
3. 
4. 
5. 
6. 
C. Other surgical procedures: [in the past 6 months] NO YES 
Type (Specify): 1. 
2. 
3. 
4. 
5. 
6. 
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  Page 6 
Patient initials Centre number Patient number 
SECTION - 6/A 
Arthropathy assessment 
CHILDREN 
(for patients older than 16 years GO TO Section 6-B) 
Hemophilia Joint Health Score 
ESCHQoL Med Doc 
Ankle Elbow Knee other 
L R L R L R 
Swelling: 0:none; 1:mild; 2:moderate; 3:severe
Duration (swelling): 1:<1 month; 2:>1month
Muscle atrophy: 0:none; 1:mild; 2:severe
Axial alignment: measured only at knees and ankle
0:within normal limits 
1:outside normal limits (see guidelines) 
Crepitus of motion: 0:none; 1:mild; 2:severe
Flexion loss: 0:no loss; 1:loss of < 10°;
2:loss of 11° to 20°; loss of >20° 
Extention loss: from hyperextention
0:no loss; 1:loss of < 10°; 2:loss of  11° to 20°; 3:loss of > 20° 
Instability: 0:none; 1:present and significant joint laxity
Joint pain on motion: 0:no complaint of pain;
1:complaint of pain; 2:complaint of pain with wincing 
3:wincing and attempts to withdraw 
Gait*: 
0:normal walking, running, galloping, skipping, stairs 
1:normal walking, abnormal (running, galloping, skipping or stairs) when stressed 
3:abnormal walking 
*Abnormalities:limping, walking with foot turned out, walking on side of foot, no push off,
walking on toes, uneven strides, no/uneven weight shifting, abnormal running, galloping, skipping or stairs
Strength:
(using modified Kendall 5 point scale)-within available ROM
0:holds test position against strong pressure (5)
1:holds test position against slight 7 moderate pressure (-4 to +4)
2:holds test position against slight  pressure (3 to +3)
3:unable to move through available ROM
4:no muscle contraction
Total
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Left knee 
0  1  2 normal
 8-15° valgus >15° valgus 
(0-7° valgus)  or 0-5° varus or >5° varus
Right knee 
0 1 2 
normal 8-15° valgus >15° valgus 
(0-7° valgus) or 0-5° varus or >5° varus
Left elbow 
0  1  2 normal
 8-15° valgus >15° valgus 
(0-7° valgus)  or 0-5° varus or >5° varus
Right elbow 
0 1 2 
normal 8-15° valgus >15° valgus 
(0-7° valgus) or 0-5° varus or >5° varus
Left ankle 
0 1 2 
no <10° valgus >10° valgus 
deformity  or <5° varus  or >5° varus
Right ankle 
0 1 2 
no <10° valgus >10° valgus 
deformity  or <5° varus  or >5° varus
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Patient initials Centre number Patient number 
ESCHQoL Med Doc 
SECTION - 6/B 
Arthropathy assessment 
ADULTS 
(for patients younger than 17 years GO BACK TO Section 6-A) 
Orthopaedic Joint Score (WFH modified) 
Ankle Knee Elbow Shoulder Hip 
Swelling (0:none;
2:present; 3:chronic) 
Muscle atrophy 
(0:no; 2:yes [>2 cm]) 
Crepitus on motion 
(0:absent; 1:present) 
L R L R L R L R L R 
Loss of Range of motion 
(0:<10%; 1:10-33%; 2:>33%) 
Flexion contracture 
(0:no; 1:<15°; 2:>15°) 
Instability (0:none;
1:present, not interfering; 
2:function deficit or bracing 
Presence of chronic pain (in the past 6 months) 
(Definition: pain present without an apparent bleed, 
recurrent at least twice a week and lasting >3 hours without treatment) NO YES 
Deambulation: normal bracing cane crutch wheel chair others 
Axial deformity 
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Patient initials Centre number Patient number 
ESCHQoL Med Doc 
SECTION - 7 
Treatment modality 
A. Age at first infusion: months 
B. Is the patient currently on home treatment: NO YES 
C. Who has mainly administered the therapy in the past 6 months: 
self administered a family member 
physician at the center nurse at the center 
general practioner nurse at hometown other hospital 
D. How is the patient treated? On demand, only On prophylaxis 
If the patient is on prohylaxis: 
D.1. Is the patient on primary prophylaxis? NO YES start months 
-> the answer "YES" must meet all the following criteria: 
1. Started before the 2nd bleed or before the age of two
2. Regularly administered at least 2 times a week
3. Continuosly administered at least 45 weeks a year
(respectively 23 weeks in the past 6 months) 
Dosage per administration: IU/Kg No. of administration per week 
D.2. Is the patient on secondary prophylaxis? NO YES start months 
-> the answer "YES" must meet all the following criteria: 
1. Started after the 2nd bleed or after the age of two
2. Regularly administered at least 2 times a week
3. Continuosly administered at least 45 weeks a year
(respectively 23 weeks in the past 6 months) 
Dosage per administration: IU/Kg No. of administration per week 
D.3. Has the patient been on intermittent prophylaxis  in the past 6 months ? 
NO YES 
-> the answer "YES" must meet all the following criteria: 
1. Regularly administered at least 2 times a week
2. Continuosly administered less than 45 weeks a year
(respectively 23 weeks in the past 6 months) 
Dosage per administration: IU/Kg No. of administration per week 
D.4. Weeks on prophylaxis in the past 6 months: weeks 
E. Venous access type in the past 6 months: 
1. peripheral vein
2. arterovenous fistula
3. central line Port-a-cath 
Broviac/Hickman 
Other (specify) 
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Drug Posology Days on treatment 
 
Drug Posology Days on treatment 
 
 
  Page 9 
Patient initials Centre number Patient number 
ESCHQoL Med Doc 
SECTION - 8 
Type of product 
A. Types of products used No. infusions/ Total consumption 
 in the past 6 months injections 
DDAVP mg 
commercial name 
Fresh frozen plasma ml 
commercial name 
cryoprecipitate ml 
commercial name 
plasma derived FVIII/FIX concentrate IU 
commercial name 
recombinant FVIII/FIX concentrate IU 
commercial name 
prothrombin complex concentrate IU 
commercial name 
activated prothrombin complex concentrate IU 
commercial name 
recombinant FVIIa mg 
commercial name 
E. Need for blood transfusions in the past 6 months? 
NO YES If YES:  packed red cells total units: 
whole bloods total units: 
F. Drugs used for HIV treatment in the past 6 months NO YES 
If yes, specify : 
1
2
3
4
5
6 
G. Drugs used for hepatitis treatment in the past 6 months NO YES 
If yes, specify : 
1 
2 
3
4
5
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Patient initials Centre number Patient number 
ESCHQoL Med Doc 
SECTION - 9 
Medical visits 
Please, answer to each question 
A. Number of visits at the Hemophilia Center in the past 6 months 
None programmed for bleedings 
B. Number of visits at the general practitioner's in the past 6 months 
None haemophilia-related for other problems 
C. Number of days of assisted physio-therapy in the past 6 months 
None at home in a center 
D. Number of visits at psychoterapist/psychologist in the past 6 months 
None private public 
E. Number of hospitalisation in the past 6 months 
None haemophilia-related for other problems 
F. Number of days of hospitalization in the past 6 months 
None haemophilia-related for other problems 
E.1. Of these how many days in an Intensive Care Unit 
None haemophilia-related for other problems 
G. Number of school/work/normal life days lost in the past 6 months 
None haemophilia-related for other problems 
H. No. of school/work/normal life days lost by patient's care-givers in the past 6 months: 
None haemophilia-related for other problems 
I. Number of visits at other specialists outside the haemophilia centre in the past 6 months 
specialist: 
No. public  or private 
No. public  or private 
No. public  or private 
personal costs for private visits in the past 6 months : Euros 
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